



Extensively Drug-Resistant *Klebsiella pneumoniae* Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition

✉Elias Eger,^a Michael Schwabe,^a Lukas Schulig,^b Nils-Olaf Hübner,^c Jürgen A. Bohnert,^d Uwe T. Bornscheuer,^e ✉Stefan E. Heiden,^a Justus U. Müller,^a Fazal Adnan,^f ✉Karsten Becker,^d Carlos L. Correa-Martinez,^g Sebastian Guenther,^h Evgeny A. Idelevich,^{d,i} Daniel Baecker,^b ✉Katharina Schaufler^{a,j}

^aPharmaceutical Microbiology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany

^bPharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald, Germany

^cCentral Unit for Infection Prevention and Control, University Medicine Greifswald, Greifswald, Germany

^dFriedrich Loeffler-Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany

^eBiotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Greifswald, Germany

^fAtta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan

^gInstitute of Hygiene, University Hospital Münster, Münster, Germany

^hPharmaceutical Biology, Institute of Pharmacy, University of Greifswald, Greifswald, Germany

ⁱInstitute of Medical Microbiology, University Hospital Münster, Münster, Germany

^jInstitute for Infectious Diseases, Christian Albrecht University and Schleswig-Holstein University Medical Center Kiel, Kiel, Germany

ABSTRACT The ability of extensively drug-resistant (XDR) *Klebsiella pneumoniae* to rapidly acquire resistance to novel antibiotics is a global concern. Moreover, *Klebsiella* clonal lineages that successfully combine resistance and hypervirulence have increasingly occurred during the last years. However, the underlying mechanisms of counteracting fitness costs that accompany antibiotic resistance acquisition remain largely unexplored. Here, we investigated whether and how an XDR sequence type (ST)307 *K. pneumoniae* strain developed resistance against the novel drug combination ceftazidime-avibactam (CAZ-AVI) using experimental evolution. In addition, we performed *in vitro* and *in vivo* assays, molecular modeling, and bioinformatics to identify resistance-conferring processes and explore the resulting decrease in fitness and virulence. The subsequent amelioration of the initial costs was also addressed. We demonstrate that distinct mutations of the major nonselective porin OmpK36 caused CAZ-AVI resistance that persists even upon following a second experimental evolution without antibiotic selection pressure and that the *Klebsiella* strain compensates the resulting fitness and virulence costs. Furthermore, the genomic and transcriptomic analyses suggest the envelope stress response regulator *rpoE* and associated RpoE-regulated genes as drivers of this compensation. This study verifies the crucial role of OmpK36 in CAZ-AVI resistance and shows the rapid adaptation of a bacterial pathogen to compensate fitness- and virulence-associated resistance costs, which possibly contributes to the emergence of successful clonal lineages.

IMPORTANCE Extensively drug-resistant *Klebsiella pneumoniae* causing major outbreaks and severe infections has become a significant challenge for health care systems worldwide. Rapid resistance development against last-resort therapeutics like ceftazidime-avibactam is a significant driver for the accelerated emergence of such pathogens. Therefore, it is crucial to understand what exactly mediates rapid resistance acquisition and how bacterial pathogens counteract accompanying fitness and virulence costs. By combining bioinformatics with *in vitro* and *in vivo* phenotypic approaches, this study revealed the critical role of mutations in a particular porin channel in ceftazidime-avibactam resistance development and a major metabolic

Editor Amit Singh, Indian Institute of Science Bangalore

Copyright © 2022 Eger et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Katharina Schaufler, katharina.schaufler@uni-greifswald.de.

The authors declare no conflict of interest.

Received 13 January 2022

Accepted 30 March 2022

Published 18 April 2022

regulator for ameliorating fitness and virulence costs. These results highlight underlying mechanisms and contribute to the understanding of factors important for the emergence of successful bacterial pathogens.

KEYWORDS XDR, ST307, *OmpK36*, experimental evolution, fitness and virulence compensation, *RpoE*

Challenged by the increasing occurrence of extensively drug-resistant (XDR) (1–3) and even pan-drug-resistant (PDR) (4–6) *Klebsiella pneumoniae* strains, which are nonsusceptible to almost all classes of antibiotics (7), reliable treatment of health care- and community-associated infections caused by these pathogens poses a serious concern to the physician. The World Health Organization (WHO) ranked carbapenem-resistant *K. pneumoniae* as one of the most critical priority pathogens. This highlights the need for the development of novel antibiotics and treatment options (8). One recent example for the latter is the fixed-dose drug combination ceftazidime-avibactam (CAZ-AVI; ratio of 4:1). The United States Food and Drug Administration (FDA) approved and introduced CAZ-AVI on the market in 2015, followed by the European Medicines Agency (EMA) 1 year later (9).

While ceftazidime (CAZ) is an established third-generation cephalosporin, avibactam (AVI) is the first approved non- β -lactam β -lactamase inhibitor (10). AVI possesses potent activity against β -lactamases belonging to Ambler classes A (extended-spectrum β -lactamases [ESBL]; e.g., CTX-M-15 and *K. pneumoniae* carbapenemases [KPC]), C (AmpC β -lactamases), and D (oxacillinases; e.g., OXA-48). However, like other serine-acylating β -lactamase inhibitors, AVI cannot inhibit metallo- β -lactamases (MBL; e.g., NDM-1, Ambler class B) (11). Therefore, treating acute and life-threatening infections caused by XDR *K. pneumoniae* strains positive for both MBL and non-MBL (such as CTX-M-15 and OXA-48) by applying CAZ-AVI in combination with the only clinically available monobactam aztreonam (ATM), which is not inactivated by MBL (12), might represent the last possible therapy option. This combination was used, for example, to treat an outbreak caused by sequence type (ST)307 *K. pneumoniae* in different health care institutions in Western Pomerania (Germany) (1, 13) and an outbreak by ST147 *K. pneumoniae* in a hospital in Barcelona (Spain) (14). Studies have previously reported CAZ-AVI and ATM-AVI resistances in *Enterobacterales*. The respective strains showed decreased membrane permeability through changes of outer membrane proteins (OMPs) (15), induction of efflux (16), modification of the targeted penicillin-binding protein 3 (PBP3) (17), or point mutations in active sites of β -lactamases (e.g., Lys237Gln of CTX-M-15 [18], Pro68Ala in combination with Tyr211Ser of OXA-48 [19], and Ala172Thr of KPC-3 [20]). The broad genetic diversity and range of known and unknown mechanisms of antimicrobial resistance acquisition underline the continued need for the further and in-depth characterization of resistance determinants.

In addition to “classical” carbapenem-resistant *K. pneumoniae* (cKp) described above, there is the hypervirulent *K. pneumoniae* (hvKp) pathotype (21–23). The latter is defined by its general susceptibility to antibiotics, the community association of infections caused, and high-level virulence, which is characterized phenotypically by hypermucoviscosity and extensive siderophore secretion (24–27). Clinically, infections caused by hvKp are often invasive and include, for instance, pyogenic liver abscess, pneumonia, endophthalmitis, meningitis, necrotizing fasciitis, and bacteremia (22). Alarming, the convergence of both cKp and hvKp has already been frequently described (1, 2, 28), which blurs the boundaries between the pathotypes. This phenomenon is seemingly driven not only by the exchange of resistance (29–31) and virulence plasmids (28, 32) but also by the chromosomal integration of DNA sequences with uncommonly high length (23, 33–35) as well as rearranged “mosaic” plasmids that carry both resistance- and virulence-associated genes (1, 36–38). We have previously reported on such mosaic plasmids, which do not necessarily reduce bacterial fitness, in the above-mentioned ST307 *K. pneumoniae* clonal lineage (1). Thus, this apparent ability of bacterial pathogens to improve their fitness




FIG 1 Schematic presentation of the experimental design. To investigate the resistance acquisition against CAZ-AVI, we inoculated 12 randomly chosen single colonies of PBIO2003 individually in 1 mL of MH-2 and incubated them overnight (preculture). Then, the stationary-phase cultures were transferred daily in the presence of increasing CAZ-AVI concentrations until some replicates tolerated concentrations of 16/4 $\mu\text{g/mL}$ CAZ-AVI. We then used a second EE approach to investigate compensatory events overcoming (putative) fitness burdens. One population, each of 2003.2 and 2003.9, was propagated in LB or MH-2, and an everyday stationary-phase culture was transferred into fresh medium.

through plasmid adaptation and compensatory mutations might explain the success of some clonal lineages (39). However, due to the redundancy and epistasis of genes and complexities of underlying pathways (40, 41), little is known about how and which mutations and regulatory mechanisms counteract fitness reduction (and associated virulence) caused by antimicrobial resistance acquisition (39).

Here, we investigated (i) the acquisition of resistance against CAZ-AVI as well as cooccurring resistances of a clinical *K. pneumoniae* strain and (ii) underlying mechanisms following an experimental evolution (EE) approach. Then, we explored (iii) whether and how this resistance acquisition might be compensated, again based on EE and downstream analyses. Overall, by combining a comprehensive set of *in vitro* and *in vivo* experiments with genomic and transcriptomic analyses, we reveal deep insights into the resistance evolution against CAZ-AVI and accompanied compensatory mechanisms to ameliorate fitness and virulence costs in XDR *K. pneumoniae*.

RESULTS

Increased tolerance against CAZ-AVI and ATM due to reduced membrane permeability. The emergence of XDR *K. pneumoniae* has been frequently described (1–3). However, we do not yet fully understand the underlying mechanisms and dynamics of resistance acquisition, especially against newer antibiotics and drug combinations. One objective of this study was thus to investigate resistance development against CAZ-AVI. We used a well-characterized XDR, yet CAZ-AVI-sensitive, ST307 *K. pneumoniae* strain (PBIO2003) (1) obtained from the outbreak mentioned earlier that took place in four different health care institutions in Western Pomerania (Germany) in 2019 and the beginning of 2020. Compared to the other ST307 isolates from the outbreak, PBIO2003 had lost the *bla*_{NDM-1} gene and, therefore, showed susceptibility to CAZ-AVI and CAZ-AVI combined with ATM.

Originally, we started with 12 biological replicates and a concentration of 0.125/0.03 $\mu\text{g/mL}$ CAZ-AVI (one-fourth MIC; Fig. 1). With daily increasing concentrations of up to 16/4 $\mu\text{g/mL}$ CAZ-AVI (which is considered resistant according to the European Committee on Antimicrobial Susceptibility Testing [EUCAST] guidelines [42]), we obtained overall two resistant replicates (16.67%, 2/12) within 14 days.

When comparing the CAZ-AVI-resistant mutants (subsequently termed 2003.2 and 2003.9) with the genome of the ancestral wild-type strain (PBIO2003), our analysis revealed different mutations in the *ompK36* gene (Fig. 2). This gene encodes an OMP




FIG 2 Different mutations of *ompK36* change the outer membrane proteins' architecture and reduce CAZ, AVI, and ATM uptake. (a) Schematic presentation of genetic changes in the *ompK36* gene of the CAZ-AVI-resistant mutants 2003.2 and 2003.9. The different mutations are marked (Continued on next page)

(designated porin) orthologue of *Escherichia coli* OmpC (43). Porins are β -barrel proteins composed of antiparallel β -sheets, thus forming an essential aqueous transmembrane channel system (44). For 2003.2, we found a nonsense single-nucleotide polymorphism (SNP) of *ompK36* (436C>T [Gln146*]; Fig. 2a), resulting in a premature stop codon and ultimately truncated translation, which usually leads to a nonfunctional protein. To further explore the molecular effects of this mutation, we predicted the protein structure of OmpK36 by homology modeling (Fig. 2b, d, and f). As shown in Fig. 2d, the protein structure model of the premature stop codon mutation supported our prediction regarding loss of function due to the absence of large parts of the porin channel transmembrane region. Additionally, we identified a read-through mutation in *dsbA* (624A>T [*208Tyr]) with a putative in-frame C terminus extension of 16 amino acids in 2003.2 that may lead to changes in protein expression levels and stability (45). This gene encodes a thiol-disulfide interchange protein, typically required for disulfide bond formation in periplasmic proteins such as OmpA (46, 47). The second mutant (2003.9) showed a fragment deletion 78 bp in length (corresponding to 26 codons), resulting in an intact reading frame with a predicted deletion of transmembrane β -sheets between the external loops L7 and L8 and a reduced pore diameter (Fig. 2b and f). Note, however, that the structure generated for 2003.9 does not represent a complete atomistic model but is instead used to visualize a significant decrease of the β -barrel diameter, explaining the possible resistance mechanism.

We then used a matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF MS) approach to identify the expressed outer membrane proteins and evaluate our predicted phenotypes (Fig. 2c, e, and g). Mutant 2003.2 (premature stop codon mutation; Fig. 2e) revealed a lack of the OmpK36 signal (m/z of 38,933). Interestingly, we also obtained no signal associated with the OmpA channel (m/z of 36,026). The β -strand-deleted variant (2003.9; Fig. 2g) showed a shift of the OmpK36 signal based on mass loss (m/z of 38,465). Notably, both the wild-type strain PBIO2003 (Fig. 2c) and mutants (2003.2 and 2003.9) showed only a low coverage of the *ompK35* annotation. This was consistent with our findings in the MALDI-TOF MS examination of the outer membrane proteins (m/z_{expected} of 37,926).

It is well known that cross-resistance (48) and collateral sensitivity (49) may accompany resistance acquisition. To further investigate the effect of the aforementioned mutations on the antibiotic resistance profile, we determined MICs of a large panel of relevant antibiotic drugs and combinations (Table S1 in the supplemental material). Phenotypic antimicrobial susceptibility testing (AST) revealed for 2003.2 and 2003.9 a strong increase not only of CAZ-AVI MIC values ($>64/4 \mu\text{g/mL}$ CAZ-AVI) but also of CAZ-AVI in combination with ATM ($>64/4/64 \mu\text{g/mL}$ CAZ-AVI/ATM). Interestingly, we found no evidence of collateral sensitivity as described previously in another study (50). We then analyzed potential differences in the compound uptake of each of the triple combination of the β -lactam antibiotics ATM and CAZ and the non- β -lactam β -lactamase inhibitor AVI. Therefore, we used a high-resolution continuum-source molecular absorption spectrometry (HR CS MAS) approach to determine changes in endogenous sulfur content following treatment with the sulfurous compounds (Fig. 2e and g). Both mutants showed similar trends of relative uptake reductions compared to PBIO2003, whereby the uptake of CAZ and AVI seemed highly affected by the reduced outer membrane permeability. However, while the uptake of CAZ was significantly reduced by up to 71.3% (PBIO2003 versus 2003.2: $P = 0.0019$) and 88.4% (PBIO2003 versus 2003.9: $P = 0.0014$), respectively, ATM uptake was reduced by only about one-third (PBIO2003 versus 2003.2: 37.9%, $P = 0.0012$;

FIG 2 Legend (Continued)

at their respective positions (red). (b, d, and f) Cartoon representation of modeled protein structures of the trimeric OmpK36 of PBIO2003 (wild-type; b), 2003.2 (premature stop codon; d), and 2003.9 (deletion of β -sheets between the external loops L7 and L8; f). Predicted changes in the architecture of the porin channel in lateral view (left) are colored in transparent gray. (c, e, and g) Mass spectra of outer membrane proteins represent differences in the configuration of expressed proteins of 2003.2 (e) and 2003.9 (g) compared to PBIO2003 (c). The insets show that changes in membrane permeability reduce CAZ, AVI, and ATM uptake into 2003.2 and 2003.9. The results are given as mean values of percent relative reduction related to PBIO2003 and standard error ($n = 3$). The results were analyzed using a one-sample t test, and the following indicate the significance level (P value): *, $P < 0.05$; **, $P < 0.01$; ****, $P < 0.0001$.

PBIO2003 versus 2003.9: 32.6%, $P = 0.0450$). The uptake of AVI was almost no longer measurable (PBIO2003 versus 2003.2: 99.3%, $P < 0.0001$; PBIO2003 versus 2003.9: 97.6%, $P < 0.0001$), thus supporting the role of OmpK36 in resistance acquisition against CAZ-AVI and ATM.

In summary, our results suggest that the decreased membrane permeability through mutation of the *ompK36* gene conferred resistance against CAZ-AVI and CAZ-AVI/ATM. Moreover, similar changes in MICs and comparable reduction in compound uptake indicate that the expression of OmpK36 with reduced pore diameter (2003.9) is as effective as the complete deletion of the porin (2003.2). In addition, we show that the uptake of the bridged 1,6-diazabicyclo[3.2.1]octan-7-one derivative AVI is highly dependent on OmpK36, which may suggest cross-resistance to other members of this class of diazabicyclooctanes β -lactamase inhibitors (e.g., nacubactam or zidebactam).

Membrane impermeability negatively affects growth, virulence, resilience, and mortality. Although porin changes conferring reduced membrane permeability have been frequently described, those mutants rarely cause outbreaks (18). This might be explained by the fact that modification of nonspecific porins leads to a fitness reduction and/or, subsequently, a decrease of virulence (51–55). This is why we challenged the porin mutants 2003.2 and 2003.9 in phenotypic experiments, including growth, virulence, resilience, and *in vivo* mortality, to investigate whether these mutations influence clinically relevant features important for bacterial pathogenesis (Fig. 3).

We observed significantly decreased growth behaviors in LB for both mutants compared to wild-type PBIO2003 (area under the growth curves [AUC] of 60.61; Fig. 3a and b), with 2003.2 (AUC of 39.72, $P < 0.0001$) showing a higher decrease than 2003.9 (AUC of 50.08, $P < 0.0001$).

We next determined siderophore secretion and mucoid phenotypes to investigate whether the growth decrease was associated with a lower virulence level (Fig. 3c and d). The biosynthesis and secretion of siderophores, which are small iron-chelating compounds that seize iron from the host (56), play a crucial role during bacterial infection and are hallmarks of hypervirulent *K. pneumoniae* (57). Our analysis revealed a significant decrease of siderophore secretion for 2003.2 (48.3%, $P < 0.0001$) and 2003.9 (67.3%, $P = 0.0102$) compared to PBIO2003 (71.3%; Fig. 3c). Another important virulence-associated feature of pathogenic *K. pneumoniae* is capsule formation, which functions as a physiological barrier and conveys protection against the hosts' immune system (e.g., protection from phagocytosis) (58, 59). Hypermucoviscosity quantification is based on prolonged sedimentation and the following retaining of mucus in the supernatant after centrifugation of hypermucoviscous cells (60). Here, the mutant cells almost entirely sedimented and formed a tighter pellet than the wild-type cells (PBIO2003: 0.225), thus indicating decreased mucoviscosity (Fig. 3d). Again, we noticed a higher decrease in this virulence-associated feature in 2003.2 (0.061, $P < 0.0001$) than in 2003.9 (0.134, $P = 0.0001$).

Since *K. pneumoniae* is a leading cause of pyogenic liver abscesses (61–64) and bacteremia (65, 66), its resilience against bile salts and serum seems essential for pathogenesis. Therefore, and to investigate the impact of reduced membrane permeability on bacterial stress response and resilience, we challenged the mutants with complement-containing human serum and bile salts for 4 h each. We observed a significant decrease in survival of the OmpK36 mutants in response to both external stressors, which indicates reduced pathogenicity of 2003.2 and 2003.9 compared to PBIO2003 (Fig. 3e and f).

We finally performed a larvae infection model of the greater wax moth *Galleria mellonella* to study the mutants' ability to cause infection-associated mortality *in vivo* (67). We injected equivalent numbers of CFU of the wild-type and both OmpK36 mutants in the right proleg and monitored the death of larvae every 24 h. When injecting 2×10^4 CFU of PBIO2003 per larvae, we detected a mortality rate of 13.3% after 24 h and 46.7% after 72 h of incubation (Fig. 3g). When using the same inoculation size of 2003.2 and 2003.9, we observed 100% larval survival 72 h after injection. Mortality rates increased slightly when higher concentrations of the




FIG 3 Phenotypic characteristics of the CAZ-AVI-resistant mutants 2003.2 and 2003.9. (a and b) Gompertz growth-fitting curves of the growth kinetics in LB ($n = 3$; a) and statistical comparison of area under the growth curves (AUC; b). The results are (Continued on next page)

mutants (2×10^5 CFU) were used, but they remained significantly lower than for the wild-type (Fig. 3h).

Adaptive mechanisms increase fitness, virulence, and resilience while resistance is retained. While previous studies frequently showed that *ompK36* mutations reduce fitness (51–55), it remains mostly unclear whether and how exactly this might be compensated. Ameliorating these costs may also play a crucial role in the emergence and maintenance of resistance within the bacterial population (68), even without antibiotic selection pressures. We thus performed a second EE experiment and evolved both 2003.2 and 2003.9 mutants (Fig. 1) to explore potential compensatory events that occur independently of antibiotic selection pressures. Since different growth conditions might directly affect evolutionary adaptation (69, 70), we used two complex media to increase the chance of identifying actual beneficial mutations. The first was LB medium, which contains no fermentable sugars and primarily provides amino acids as a carbon source (71). The second was cation-adjusted Mueller-Hinton broth 2 (MH-2), which is formulated for antimicrobial susceptibility testing according to EUCAST guidelines (42).

During the second EE, we tracked the growth behaviors of each population every fifth day. Noticeably, after 15 days of serially passaging in LB and 25 days in MH-2, a fitness behavior of the evolved variants comparable to the growth of wild-type PBIO2003 was observed (Fig. 4a and b). Hence, compared to their parental strain 2003.2 (competitive index [CI] of 0.0060), the adapted variants 2003.2^{LB} (CI of 0.4480, $P = 0.0002$) and 2003.2^{MH-2} (CI of 0.1547, $P = 0.0344$) showed a significant increase in growth and competition. However, 2003.9^{LB} (CI of 0.2041, $P = 0.2505$) and 2003.9^{MH-2} (CI of 0.2117, $P = 0.2230$) exhibited only weak changes in their growth behaviors compared to the parental mutant 2003.9 (CI of 0.0647).

We hypothesized that fitness recovery is accompanied by an increase in virulence and resilience. We thus tested the adapted variants in our set of phenotypic experiments (Fig. 4c to f). Compared to the parental strain 2003.2, the adapted variants 2003.2^{LB} and 2003.2^{MH-2} showed a significant increase in siderophore secretion (Fig. 4c; 2003.2 48.3% and 2003.2^{LB} 84.7%, $P < 0.0001$; 2003.2^{MH-2} 83.9%, $P < 0.0001$) and mucoviscosity (Fig. 4d; 2003.2 0.061 and 2003.2^{LB} 0.182, $P = 0.0003$; 2003.2^{MH-2} 0.155, $P = 0.0013$). In addition, we observed a significant increase in resilience toward human serum and bile salts (Fig. 4e and f). In contrast, changes in the adapted variants 2003.9^{LB} and 2003.9^{MH-2} compared to their parent 2003.9 seemed slightly different. Again, we obtained a significant increase in siderophore production (Fig. 4c; 2003.9 67.3% and 2003.9^{LB} 84.4%, $P = 0.0003$; 2003.9^{MH-2} 84.2%, $P = 0.0003$) and mucoviscosity (Fig. 4d; 2003.9 0.134 and 2003.9^{LB} 0.207, $P = 0.0044$; 2003.9^{MH-2} 0.261, $P = 0.0003$), respectively. However, only 2003.9^{LB} showed a significant increase in serum resistance (Fig. 4e), and, interestingly, 2003.9^{LB} and 2003.9^{MH-2} showed a significant decrease in tolerance against bile salts (Fig. 4f) compared to 2003.9. Notably, the *G. mellonella* larvae infection model revealed increased mortality caused by each adapted variant originating from 2003.2 and 2003.9. By injecting 2×10^5 CFU of 2003.2^{LB} and 2003.2^{MH-2} per larvae, respectively, we detected mortality rates of 20.0% (2003.2^{LB}) and 26.7% (2003.2^{MH-2}) after 24 h and 56.7% (2003.2^{LB}) and 40.0% (2003.2^{MH-2}) after 72 h of incubation (Fig. 4g). When using the same inoculation volume of 2003.9^{LB} and 2003.9^{MH-2} (Fig. 4h), we observed mortality rates of 30.0% (2003.9^{LB}) and 23.3% (2003.9^{MH-2}), resulting in overall mortality rates of 56.7% (2003.9^{LB}) and 40.0% (2003.9^{MH-2}) after 72 h.

FIG 3 Legend (Continued)

given as mean values and standard deviation of AUCs. (c) The extent of secreted siderophore is presented as mean values of the siderophore production unit and standard deviation ($n = 3$). (d) Determination of mucoid phenotype using a sedimentation assay ($n = 3$). The results are given as mean ratios of OD₆₀₀ of supernatant after centrifugation at $1,000 \times g$ for 5 min and total OD₆₀₀ and standard deviation. (e) Survival in 50% human serum ($n = 3$). The results are given as mean values and standard deviation of log₂ fold change of CFU/mL after 4 h of incubation in the presence of serum. (f) Resilience against 50 mg/mL bile salts ($n = 3$). The results are shown as mean percent survival rates and standard deviation. (g and h) Kaplan-Meier plot of mortality rates in the *Galleria mellonella* larvae infection model ($n = 3$). The results are given as mean percent mortality following injection of 2×10^4 CFU/larvae (g) and 2×10^5 CFU/larvae (h). For all results, the mutants were compared to PBIO2003 using variance analyses (one-way ANOVA with Dunnett's multiple comparison *post hoc* test); *, $P < 0.05$; ***, $P < 0.001$; ****, $P < 0.0001$.




FIG 4 Phenotypic changes of the adapted variants of 2003.2 and 2003.9. (a) Gompertz growth-fitting curves of the growth kinetics in LB ($n = 3$). (b) Quantification of competitive interactions. The results are given as mean values and standard deviation (Continued on next page)

In summary, with the second EE experiment, we obtained adapted variants that seemingly restored their fitness and virulence compared to the original wild-type strain. To assess the underlying mechanisms of these compensatory events, we next performed genomic analyses. When comparing the genomes of 2003.2^{LB} and 2003.2^{MH-2} with the parental strain 2003.2, our analysis revealed that the premature stop codon in *ompK36* and the read-through mutation of *dsbA* were still present. Moreover, we identified two different missense mutations in *rpoE* (2003.2^{LB}: 154G>A [Glu52Lys]; 2003.2^{MH-2}: 97G>T [Val33Phe]), encoding one of the primary regulators of the enveloped stress response system, which is activated through accumulated misfolded proteins and lipopolysaccharide (LPS) fragments in the periplasmic space (72, 73). Upon alternative sigma factor E (σ^E) triggering, it forms a holoenzyme with the bacterial core RNA polymerase complex (RNAP) and initiates transcription of more than 100 protein-coding genes, such as proteins required for DNA recombination and repair, lipid A biosynthesis, and LPS translocation as well as OMP membrane insertion (74, 75). Interestingly, both missense mutations were located in the highly conserved domain σ^E_2 , which stabilizes the transient association of σ^E with the RNAP, thus forming the active holoenzyme and initiating transcription (76). Therefore, these *rpoE* mutations might destabilize the RNAP binding, resulting in decreased transcription levels of RpoE-regulated genes. Furthermore, this might reduce the ability of σ^E to compete with the other sigma factors for RNAP (77).

In contrast to the variants of 2003.2, when comparing the genomes of 2003.9^{LB} and 2003.9^{MH-2} with 2003.9, we only identified the expected deletion of transmembrane β -sheets between the loops L7 and L8 of *ompK36* but no other mutations.

Pathogenic bacteria rapidly respond to surrounding changes during different stages of infection by transcriptomic regulation (78, 79). These complex regulatory networks not only protect the cell from external stressors but also improve fitness and the expression of virulence-associated features such as enhanced iron uptake (79, 80). While costly genetic modifications in the *ompK36* gene in the presence of CAZ-AVI represent an advantageous trade-off, reduced membrane permeability in the absence of antibiotics itself is a stressor that resistant strains must cope with. This might be reflected by significant transcriptomic changes to compensate for fitness costs and overcome high cellular stress levels. This is why we next examined the transcriptomes of the adapted variants 2003.2^{LB}, 2003.2^{MH-2}, 2003.9^{LB}, and 2003.9^{MH-2} compared with their parental strains 2003.2 and 2003.9, respectively (Fig. S1 to S3 in the supplemental material). The Clusters of Orthologous Groups (COG) analysis revealed an upregulation of genes encoding cell motility and extracellular structures in all adapted variants (Fig. S4 and S5 in the supplemental material). However, the adapted variants showed extensive downregulation of genes associated with information storage and processing, cellular processes and signaling, and metabolism. Interestingly, differential gene expression (DGE) analysis of 2003.2^{LB} and 2003.2^{MH-2} compared with 2003.2 revealed significant downregulation of genes whose transcription is induced by σ^E , thus supporting our hypothesis that both missense mutations of *rpoE* resulted in a loss of function of this alternative sigma factor (Fig. S4 in the supplemental material). These downregulated σ^E regulon genes are required for proper folding and assembly of OMPs (*bamACDE*, *fkpA*, *skp*), phospholipid and LPS biogenesis and modification (*eptB*, *lpxP*, *phoP*), cellular processes and regulation (*csrD*, *cutC*, *htrA*, *rpoE*, *rseP*), as well as

FIG 4 Legend (Continued)

of competitive indices (CIs). (c) The extent of secreted siderophore is presented as mean values of the siderophore production unit and standard deviation ($n = 3$). (d) Determination of mucoid phenotype by using a sedimentation assay ($n = 3$). The results are given as mean ratios of OD₆₀₀ of supernatant after centrifugation at $1,000 \times g$ for 5 min and total OD₆₀₀ and standard deviation. (e) Survival in 50% human serum ($n = 3$). The results are given as mean values and standard deviation of log₂ fold change of CFU/mL after 4 h of incubation in the presence of serum. (f) Resilience against 50 mg/mL bile salts ($n = 3$). The results are shown as mean percent survival rates and standard deviation. (g and h) Kaplan-Meier plot of mortality rates in the *Galleria mellonella* larvae infection model ($n = 3$). The results are given as mean percent mortality following injection of 2×10^5 CFU/larvae. For all results, the adapted variants were compared to their respective parental strain using variance analyses (one-way ANOVA with Dunnett's multiple comparison *post hoc* test); ns, not significant; *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$.

unknown functions (*yfeXY*) (75, 81). Furthermore, we noticed an upregulation of genes encoding porins (*ompA*, *ompK36*), which is usually associated with the inactivation or repression of σ^E during exponential growth (74). Taken together, these results strongly support the role of RpoE suppression in regaining fitness and virulence as shown by 2003.2^{LB} and 2003.2^{MH-2} results. Also note that we detected a significant increase of *ompK17* expression for both 2003.2^{LB} and 2003.2^{MH-2}. Various studies reported that this small OMP, which is a structural homolog of OmpX of *E. coli* (82), is involved in cell adhesion and biofilm formation (83) and contributes to resistance against complement-mediated killing and *in vivo* mortality (84), thus possibly also participating in the restored phenotypes of 2003.2^{LB} and 2003.2^{MH-2}.

The DGE analysis of 2003.9^{LB} and 2003.9^{MH-2} compared to their parental strain 2003.9 revealed a significant upregulation of *nhaA* (Fig. S5 in the supplemental material), which encodes an essential sodium proton antiporter involved in enhanced pH tolerance and sodium and volume homeostasis, crucial to cell viability (85). Interestingly, a previous study showed that the deletion of *nhaA* leads to severe attenuation of virulence in pathogenic *E. coli* strains in mammalian and avian infection models (86). Moreover, an orthologue of NhaA expressed by *Yersinia pestis* contributes to bacterial survival in the bloodstreams of infected mice (87), thus indicating that NhaA might contribute to fitness and virulence regain of 2003.9^{LB} and 2003.9^{MH-2}. In addition, we detected a significant downregulation of *dksA*, an RNA polymerase-binding transcription factor, which is a part of the stringent response. Under nutrition-limited conditions, bacteria must adjust their metabolic activity and growth to maintain a balance between cell survival and proliferation. Therefore, they synthesize signaling nucleotides (ppGpp) that interact with two binding sites of RNAP, leading to transcription initiation. DksA binds to another binding site of RNAP and modulates its activity in conjunction with ppGpp (88). Additionally, in the absence of ppGpp, DksA regulates rRNA transcription initiation. A previous study demonstrated that the rRNA promoter activity of a $\Delta dksA$ mutant does not decrease following entry into the stationary phase, and the promoter does not respond to changes in growth rates or amino acid starvation (89). This might be another explanation for the fitness and virulence recovery of 2003.9^{LB} and 2003.9^{MH-2}.

Finally, we verified that the resistant phenotypes were still present in 2003.2^{LB}, 2003.2^{MH-2}, 2003.9^{LB}, and 2003.9^{MH-2} by again examining the MIC of a large panel of relevant antibiotic drugs and combinations (Table S1). Our analysis revealed that most resistance profiles of 2003.9^{LB} and 2003.9^{MH-2} strains were similar to their parental strain 2003.9. In contrast, we detected a difference regarding the last-resort antibiotic colistin in 2003.2^{LB} and 2003.2^{MH-2} (from 16 $\mu\text{g}/\text{mL}$ to 0.5 $\mu\text{g}/\text{mL}$). It is known that incorporation of phosphoethanolamine and 4-amino-4-deoxy-L-arabinose in lipid A lowers the negative charge of the bacterial LPS, which subsequently leads to resistance (90). Note that here, the aforementioned decrease of RpoE activity in 2003.2^{LB} and 2003.2^{MH-2} leads to reduced expression of genes related to these lipid A modifications (*eptB*, *lpxP*, *phoP*), resulting in exposure of the negative charge and consequent colistin susceptibility.

In summary, here we show that a resistance-accompanying decrease in fitness and virulence was compensated following bacterial evolution in the absence of antibiotic selection pressure, while CAZ-AVI resistance was still present. Our genomic and transcriptomic analyses suggest that mutations in *rpoE* and expression differences of RpoE-regulated genes were drivers of this compensation along with, however, a loss of colistin resistance due to alterations of LPS.

DISCUSSION

Although combinations of synergistically interacting drugs (such as combinations of β -lactams and β -lactamase inhibitors) are often used to treat infections, Hegreness et al. (91) showed that these combinations did not sufficiently suppress resistance acquisition. The authors concluded that mutations confer simultaneous resistance against both compounds. In particular, sublethal antimicrobial concentrations hereby appear to induce rapid mutagenesis (92). Starting with a subinhibitory concentration and daily increasing

CAZ-AVI concentrations, we obtained two different CAZ-AVI-resistant mutants within 14 days only. Although this approach does not exactly reflect a guideline-oriented therapy in clinical practice (93), the rapid resistance development is remarkable and underlines the clinical importance of our finding.

As mentioned before, combining ATM with CAZ-AVI to treat bacterial pathogens that harbor both MBL and non-MBL is a last-resort drug possibility. Since a fixed-dose product of ATM-AVI is currently unavailable, increased tolerance of pathogens against this combination has been rarely described clinically (94). Quite recently, Nordmann et al. (95) reported the occurrence of *E. coli* strains showing phenotypic nonsensitivity against ATM-AVI, however, conferred by modifications of PBP3 with cooccurrence of different β -lactamases. Our study provides evidence of mutations in *ompK36* following EE of a clinical XDR *K. pneumoniae* strain, resulting in both resistance against CAZ-AVI and nonsensitivity against CAV-AVI with ATM. We show that these mutations resulted phenotypically in nonexpression of OmpK36 (2003.2, premature stop codon) and reduced pore diameter (2003.9, deletion of transmembrane β -sheets between the loops L7 and L8), respectively. Previous studies associated alterations of OmpK35/36 channels with CAZ-AVI resistance in *K. pneumoniae* in clinical settings (96–98), but, due to the complexities in underlying genetic mechanisms, interactions of specific β -lactamases and the diversity of *ompK35/36* variants, their potency in resistance contribution remains controversial (99). For example, Pagès et al. (100) demonstrated that ESBL-producing *K. pneumoniae*, which additionally lacked one or both OmpK porins, had increased MIC values of CAZ but were still susceptible to CAZ-AVI. Hence, the authors concluded that OmpK35 and OmpK36 did not contribute to the intracellular uptake of AVI through the outer membrane. In contrast, we unequivocally verified that the combination of missing OmpK35 expression and changes in the OmpK36 channel led to almost entirely reduced uptake of the third-generation cephalosporin CAZ and the bridged 1,6-diazabicyclo[3.2.1]octan-7-one derivative AVI. Interestingly, this seems to be independent of the expression of OmpA, as 2003.9 showed similar or sometimes higher relative uptake reductions, although we detected that OmpA was expressed. Moreover, the similarity of MIC changes and reduction in compound uptake indicates that the expression of OmpK36 with reduced pore diameter is as effective as the complete deletion of the porin. Results of another study support this finding (55). Consistent with the findings of our study, the authors demonstrated that two mutation types of OmpK36 had comparable potency in the contribution of β -lactam resistance. Furthermore, OmpK35 was shown to play only a minor role in this resistance propagation; an issue that we were not able to investigate more closely due to the intrinsic absence of OmpK35 in the wild-type strain PBO2003. Overall, our results demonstrate the importance of OmpK36 in rapid resistance acquisition.

It is well-known and has been frequently described that resistance acquisition is, directly and indirectly, accompanied by a reduction of bacterial fitness and virulence (101). In fact, our porin-mutated strains 2003.2 and 2003.9 showed significantly decreased growth behaviors compared to wild-type PBO2003. Moreover, we found a strong decrease in virulence-associated features and stress resilience, as also demonstrated by reduced *in vivo* mortality. Consistent with our findings, previous studies have reported a fitness reduction and lack of virulence of strains that obtain OMP alterations (51–55), thus indicating the key role of porins in maintaining fitness and consequently virulence. Overall, our results suggest that antibiotic resistance acquisition is a double-edged sword. On the one side, it is necessary for survival in environments with respective selection pressures. On the other side, resistance acquisition comes at a cost and may lead to reduced fitness, virulence, resilience, and mortality, likely resulting in decreased competition potentials and a lack of features required for the successful adaptation to new niches and pathogenicity. Interestingly, our genomic analysis showed that the costly membrane modifications were likely not compensated by a plasmid loss. Thus, the persistence of several large plasmids under high cellular stress conditions suggests that plasmid carriage does not inevitably reduce bacterial fitness (1, 102, 103).

Several pandemic high-risk clonal lineages have been identified in recent years, which successfully combine high-level virulence and resilience (1, 103–107) with extensive drug resistance, even in more pristine environments with low antibiotic selection pressures (108–110). This combination and the nonreversibility of resistance could be due to different compensatory events that counteract fitness costs (111). However, because of the broad phylogenetic diversity of bacterial hosts and the vast spectrum of compensatory mechanisms, reports and predictions of underlying adaptive processes that occur in clinical strains remain mostly unavailable. To address these issues, we performed a second EE analysis to track adaptational changes throughout the evolutionary process. We showed that the fitness costs of 2003.2 and 2003.9 were nearly completely ameliorated when evolved in two different media for 15 days (LB) and 25 days (MH-2). This rapid adaptation to external stress associated with fitness recovery might contribute to important changes in transmission dynamics and patient prognosis during infection (112). In addition, the fitness increase was accompanied by enhanced virulence levels of 2003.2^{LB}, 2003.2^{MH-2}, 2003.9^{LB}, and 2003.9^{MH-2}. While we identified mutations in *rpoE* and subsequent changes in expression levels of genes regulated by RpoE in the genomes of 2003.2^{LB} and 2003.2^{MH-2}, our DGE analysis of 2003.9^{LB} and 2003.9^{MH-2} indicated the sole contribution of transcriptomic changes in the recovery of fitness and virulence. Note that the compensated fitness costs in the adapted variants 2003.2^{LB} and 2003.2^{MH-2} were accompanied by an increased susceptibility to colistin demonstrating collateral sensitivity, which might be a promising prospective therapeutic approach for treating chronic infections caused by XDR pathogens (49).

One limitation of our study is the “random” nature of mutations and transcriptomic and phenotypic changes, which might present differently upon repetition of the experiment. Moreover, during (experimental) evolution, numerous factors, such as variations in population size and selection pressure (113), might directly influence adaptational events. However, this does not diminish the significance of our findings but underlines the diversity of resistance evolution, compensation, and underlying processes. Another limitation is the possibility that mutations and changes in the mutants could be media adaptations that are difficult to correlate with natural circumstances (69). We cannot completely exclude this point without doubt. However, as can be seen in the DGE analysis, similar genes were up- or downregulated regardless of whether the second EE was performed in LB or MH-2 medium. The increased fitness and virulence of 2003.2^{LB}, 2003.2^{MH-2}, 2003.9^{LB}, and 2003.9^{MH-2} was thus presumably not (only) based on media adaptations. Finally, to conclusively explain the underlying mechanisms behind the phenotypes would require depletion and/or complementation studies. Therefore, additional investigations will have to address these points further. Also, it might be promising to evaluate the impact of outer membrane modifications on the protective properties of promising vaccines whose immunization response is based on OmpK36 (114–116).

Conclusion. In this study, we not only highlight the important role of OmpK36 regarding β -lactam and AVI uptake as well as its contribution to resistance acquisition but also demonstrate the disadvantageous effects of changes in OMPs on bacterial fitness and virulence. More importantly, we show that fitness costs accompanied by this resistance acquisition were compensated rapidly and that bacterial virulence was almost completely restored, enabled by particular genomic and transcriptomic adaptations that involved major bacterial regulators.

MATERIALS AND METHODS

Bacterial strains and experimental evolution. Bacterial strains used in this study are listed in Table 1. All strains were stored at -80°C in LB (Carl Roth, Karlsruhe, Germany) supplemented with 20% (vol/vol) glycerol (anhydrous; Merck, Darmstadt, Germany). Before use, one single colony from fresh overnight cultures on LB agar plates was individually inoculated in 5 mL of LB and grown under shaking conditions (130 rpm) at 37°C overnight.

To study CAZ-AVI resistance acquisition and increase the probability of receiving resistant representatives (117), we used 12 randomly chosen single colonies as individual biological replicates of PBIO2003

TABLE 1 Overview of bacterial strains used in this study

Strain	ST	Relevant characteristics or genotype	References
<i>Klebsiella pneumoniae</i>			
PBIO2003	307	Wild-type strain (rectal swab, human), ancestral strain of 2003.2 and 2003.9 <i>bla</i> _{OXA-48} , <i>bla</i> _{CTX-M-15} , <i>bla</i> _{SHV-106} , <i>bla</i> _{TEM-1B} , <i>aac(3)-IIa</i> , <i>aph(3'')-Ib</i> , <i>aph(6)-Ib</i> , <i>fosA</i> , <i>tet34</i> , <i>sul2</i> , <i>mdfA</i> , <i>oqxAB</i>	1, 13
2003.2	307	<i>ompK36</i> (Gln146*) mutated variant of PBIO2003 (first EE) Parental strain of 2003.2 ^{LB} and 2003.2 ^{MH-2}	This study
2003.2 ^{LB}	307	In LB-adapted variant of 2003.2 (second EE, 15 days)	This study
2003.2 ^{MH-2}	307	In MH-2-adapted variant of 2003.2 (second EE, 25 days)	This study
2003.9	307	<i>ompK36</i> (Δ 78 bp; 972–1,049/1,125 nt) mutated variant of PBIO2003 (first EE) Parental strain of 2003.9 ^{LB} and 2003.9 ^{MH-2}	This study
2003.9 ^{LB}	307	In LB-adapted variant of 2003.9 (second EE, 15 days)	This study
2003.9 ^{MH-2}	307	In MH-2-adapted variant of 2003.9 (second EE, 25 days)	This study
ATCC 700603	489	Laboratory reference strain (urine, human), negative control for siderophore secretion assay	143
hvkP1	86	Archetypal hypervirulent <i>K. pneumoniae</i> isolate (blood and liver, human), positive control for hypermucoviscosity assay	27, 144
<i>Escherichia coli</i>			
PBIO1289 (IMT10740)	1159	Internal reference APEC strain (environment, poultry), positive control for serum resistance and survival in bile salts	108, 145
W3110	10	Laboratory reference strain, negative control for serum resistance and survival in bile salts	146

for our first EE approach (Fig. 1). The single colonies were inoculated in 1.5-mL tubes (Carl Roth, Karlsruhe, Germany) containing 1 mL of cation-adjusted Mueller-Hinton broth 2 (MH-2; Sigma-Aldrich, St. Louis, MO, USA) and grown at 37°C and 130 rpm. Following overnight incubation, 10 μ L of bacterial precultures were transferred into a 96-well microtiter plate containing 190 μ L MH-2 supplemented with CAZ-AVI (Zavicefta, Pfizer, New York City, NY, USA), resulting in a final concentration of 0.125/0.03mg/mL CAZ-AVI. The inoculated microtiter plates were incubated at 37°C without agitation for 24 h to allow “fixation” of mutations that occurred in the later growth phase (118). Daily, 10 μ L of the culture was transferred in 190 μ L of MH-2 with increasing concentrations of CAZ-AVI until some replicates tolerated concentrations of 16/4 μ g/mL of CAZ-AVI. This is considered resistant according to the guidelines of EUCAST (42).

We then used a second EE approach to investigate compensatory events overcoming (putative) fitness burdens. One population, each of 2003.2 and 2003.9, was propagated in 5 mL of LB or MH-2 at 37°C and 130 rpm by transferring 5 μ L of stationary-phase culture into fresh medium every day. We collected samples from the populations every fifth day and stored them at –80°C until further examination.

Whole-genome sequencing. One randomly chosen single colony was cultured overnight in MH-2 supplemented with 16/4 μ g/mL CAZ-AVI. Total DNA was extracted using the MasterPure DNA purification kit for blood, version 2 (Lucigen, Middleton, WI, USA), according to the manufacturer's instructions. Isolated DNA was purity controlled and quantified using a NanoDrop 2000 and Qubit 4 fluorometer (Thermo Fisher Scientific, Waltham, MA, USA), respectively. The DNA was shipped to the Microbial Genome Sequencing Center (MiGS; Pittsburgh, PA, USA) and, following library preparation, sequenced using 2 \times 150 bp paired-end reads (Illumina NextSeq 550).

Raw sequencing reads of the parental strain PBIO2003 were processed as described before (1). The trimmed and filtered reads were mapped against the complete reference genome of the closely related strain PBIO1953 with breseq v.0.36.0 (119). Mutations evidenced by read alignments were applied to this reference with the help of the GenomeDiff tools shipped with breseq. This new reference of PBIO2003 was used for mapping sequencing reads of strains obtained through experimental evolution with breseq and deducing mutations.

Raw sequencing reads of evolved mutants were adapter-trimmed, contaminant-filtered, and quality-trimmed with BBDuk from BBTools v.38.89 (<http://sourceforge.net/projects/bbmap/>). FastQC v.0.11.9 (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) was used for quality control of both raw and trimmed reads. *De novo* genome assemblies at a maximum coverage of 100 \times were performed using shovill v.1.1.0 (<https://github.com/tseemann/shovill>) with SPAdes v.3.15.0 (120). Draft genomes were additionally polished outside the shovill pipeline by mapping trimmed reads to the contigs of the draft assemblies using BWA v.0.7.17 (121), and after processing of SAM/BAM files (sorting, marking of duplicates) with SAMtools v.1.11 (122), variants were called with Pilon v.1.23 (123).

RNA isolation and sequencing. The overnight cultures were set to 0.5 McFarland standard turbidity. Then, 3 mL of these bacterial suspensions were added to 27 mL of LB (10-fold dilution) and incubated at 37°C and 130 rpm until the optical density at λ = 600 nm (OD_{600}) reached 0.2 turbidity (early log phase). Next, 1 mL of bacterial cultures was harvested, cooled down in liquid nitrogen for 5 s to inhibit further transcriptomic activity, and centrifuged (16,000 $\times g$ for 3 min at 2°C). Finally, the supernatants were discarded entirely, and the pellets were frozen in liquid nitrogen for 2 s and stored at –20°C (not more than 6 h) until further preparation. According to the manufacturer's instructions, the total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Isolated RNA was purity-controlled and quantified using a Qubit 4 fluorometer. The RNA was shipped frozen to LGC (LGC Genomics, Berlin,

Germany) and, following rRNA depletion and mRNA library preparation, sequenced using 1×75 bp reads (Illumina NextSeq 550, nonstranded).

First, Trim Galore v.0.6.7 (<https://github.com/FelixKrueger/TrimGalore>) was used for the adapter and quality trimming of the raw sequencing reads. Next, the trimmed reads were mapped with Bowtie 2 v.2.4.4 (124) (mode: --very-sensitive-local) using the assembly of PBIO2003 as reference. Subsequently, gene counts were calculated using featureCounts v.2.0.1 (125) based on the annotation of PBIO2003. Finally, the count table was imported into R v.4.1.1 (<https://www.R-project.org/>), and differentially expressed genes were called with DESeq2 v.1.33.5 (126) in default mode, with one exception; genes with rowSums of <10 in the count table were removed before the analysis. We used an absolute 1.5 log₂ fold change threshold with an adjusted *P* value lower than 0.01 to determine differences in gene expression (127). We excluded one replicate of 2003.9^{LB} due to a shift on principal component 1 (PC1) and PC2 obtained by visual evaluation of the plotted principal-component analysis (PCA; Fig. S1 in the supplemental material). All differentially expressed genes were compared to the COG (Clusters of Orthologous Groups of proteins) database v.2020 (128, 129) using Diamond v.2.0.11.149 (130) (mode: blastP, *E* value of $\leq 10^5$).

Molecular modeling of OmpK36 protein structure. To investigate the molecular effects caused by mutations of *ompK36*, we predicted the protein structure of OmpK36 by homology modeling. The initial model for the trimeric full-length OmpK36 construct was built within the multiple sequence viewer application in Maestro v.2020-4 (Schrödinger, New York, NY, USA). In total, five models were calculated based on the template structure of Protein Data Bank (PDB) number 6RCP (54) using a knowledge-based approach with side chain optimizations. A high-quality, clash-free model was selected and subsequently prepared with the protein preparation wizard (131) in Maestro to add hydrogens, assign bond orders, and optimize protonation state, followed by a short restraint minimization. In order to obtain the structure for 2003.9, the residues Lys324 to Asp350 were simply deleted in all three monomers, and terminal residues were capped with acetyl groups at the N termini and protected *N*-methyl-amide at the C-terminal ends. CHARMM force field parameter and protein standard files (PSF) for NAMD v.2.13 (132) were prepared using CHARMM-GUI (133). Finally, hydrogen mass repartition was applied using an in-house script that enables a timestep of 4 fs (134). All stages were simulated *in vacuo* with a cutoff for non-bonded interactions at 1.6 nm, including a switching function with a 0.1-nm region. After initial minimization for 50,000 steps, the system was simulated for 4 ns NVT (constant number of particles, volume, and temperature) at 310 K. Temperature was controlled by a Langevin thermostat with a 1 ps^{-1} damping coefficient. The hydrogen bonds of β -sheet-forming residues were restrained using extra bonds with a force constant of 10.0 kcal/(mol $\times \text{\AA}^2$). Both ends of the open elliptical β -barrel were slowly contracted with harmonic potentials of 0.5 kcal/(mol $\times \text{\AA}^2$) in all three monomers simultaneously to close the region of segment deletion. Another trimeric homology was calculated from the 2003.9 sequence based on the final simulation snapshot as a template to rebuild the remaining loops with Prime (135).

Identification of outer membrane proteins by MALDI-TOF MS. The bacterial suspensions were set to 0.5 McFarland standard turbidity in deionized water, pelleted ($13,800 \times g$ for 5 min at room temperature [rt]), and resuspended in 300 μL of deionized water. Then, 900 μL of 99.8% (vol/vol) ethanol (Carl Roth, Karlsruhe, Germany) was added. Following two centrifugation steps ($9,600 \times g$ for 2 min at rt) and air drying (4 to 6 min), the pellets were resuspended in 20 μL of 70% (vol/vol) formic acid (Thermo Fisher Scientific, Waltham, MA, USA). The suspensions were mixed with 20 μL of acetonitrile (Carl Roth, Karlsruhe, Germany) and centrifuged ($9,600 \times g$ for 2 min at rt). Next, 1 μL of supernatants was spotted on a MALDI target plate (MBT Biotarget 96, Bruker Daltonik, Bremen, Germany) and left to dry at rt, and 1 μL of 130 μM 2,5-dihydroxybenzoic acid matrix (Sigma-Aldrich, St. Louis, MO, USA) was added onto each protein-containing spot. The extracted membrane proteins were analyzed by MALDI-TOF MS using a Microflex smart instrument (mass range of 2 to 40 kDa, laser intensity of 70%, number and frequency of shots of 200; Bruker Daltonik, Bremen, Germany). The analysis of spectra was performed using flexAnalysis software v.3.3 (Bruker Daltonik, Bremen, Germany).

Cellular uptake of CAZ, AVI, and ATM. The cellular uptake of the β -lactam antibiotics ATM (dissolved in water; dimethylformamide [DMF; 1:1]; Acros Organics, Geel, Belgium) and CAZ (dissolved in 0.1 M NaOH; Acros Organics, Geel, Belgium) and the non- β -lactam β -lactamase inhibitor AVI (dissolved in water; BioVision, Milpitas, CA, USA) was investigated by determining the increased cellular content of sulfur in terms of carbon monosulfide ($\lambda = 258.0330$ nm) based on uptake of the sulfurous compounds by using high-resolution continuum-source molecular absorption spectrometry (HR CS MAS) based on the graphite furnace technique. This investigation refers to experiments described previously (136) with minor modifications. First, overnight cultures were set to an OD₆₀₀ of 0.3 turbidity (approximately 1.5×10^8 CFU/mL). Then, 1 mL of these bacterial suspensions was transferred into 1.5-mL tubes and pelleted ($4,000 \times g$ for 10 min at rt). The supernatant was carefully discarded, and the pellets were resuspended in 1 mL of phosphate-buffered saline (PBS). Next, 100 μM sulfurous compound was added, and cells were incubated at 37°C without agitation. Samples containing only the solvent served as blanks. After 1 h of incubation, the cells were pelleted ($4,000 \times g$ for 10 min at rt) and washed once with 1 mL of PBS, and the collected pellets were stored at -20°C until further analysis.

For analysis, the pellets were thawed, resuspended in deionized water, and lysed by using a sonotrode (20 s, 9 cycles, 80 to 85% power; Bandelin Sonoplus, Berlin, Germany). An aliquot of the samples was spiked appropriately with the respective antibiotic and used for quantification. The measurements were performed with a contrAA 700 spectrometer (Analytik Jena, Jena, Germany). Ten microliters of the spiked samples was injected directly into pyrolytically coated graphite tubes (PIN-platform, Analytik Jena, Jena, Germany), followed by treatment applying for a time-temperature program as published before (137). Samples containing the lysate of bacteria were incubated only with the medium, and the

solvent served as a blank. Thus, the endogenous sulfur content (blank) was subtracted from the absorbances when investigating the uptake of the sulfurous compounds. The mean integrated absorbances of 2 to 3 injections were used throughout the experiments. The uptake was expressed as a percentage of relative reduction related to PBIO2003.

MIC. Phenotypic antimicrobial susceptibility testing (AST) was performed using the Vitek 2 automated system (bioMérieux, Marcy l'Etoile, France). The MIC values of CAZ-AVI, CAZ-AVI with ATM, tigecycline (dissolved in dimethyl sulfoxide [DMSO]; Acros Organics, Geel, Belgium), and chloramphenicol (dissolved in 99.8% [vol/vol] ethanol; VWR International, Radnor, PA, USA) were determined by broth microdilution according to ISO standard 20776-1. Additionally, the MIC of colistin was examined using MICRONAUT MIC-Strip colistin (Merlin Diagnostika, Bornheim, Germany) according to the manufacturer's instructions. All results were interpreted according to the published breakpoints and guidelines of EUCAST (42).

Growth kinetics and competition. Growth kinetics were assayed by continuously measuring the OD₆₀₀. Briefly, overnight cultures were diluted 1:100 in 5 mL of fresh LB and incubated at 37°C and 130 rpm until the OD₆₀₀ reached 0.5 McFarland standard turbidity. Then, the bacterial suspensions were diluted 10-fold, and 200 µL of cultures was transferred in triplicates into a 96-well microtiter plate (Nunc, Thermo Fisher Scientific, Waltham, MA, USA). Finally, the OD₆₀₀ was recorded every 30 min using a microplate reader (FLUOstar Omega, BMG LABTECH, Ortenberg, Germany) at 37°C with 200 rpm orbital shaking.

The quantitative competition was determined by coinoculation of PBIO2003 with 2003.2 and 2003.9 as well as 2003.2^{LB}, 2003.2^{MH-2}, 2003.9^{LB}, and 2003.9^{MH-2}. Here, the bacterial cultures were set to a 0.5 McFarland standard turbidity in LB as described for growth kinetics. Then, the reference (PBIO2003) and competitor strains were mixed in a 1:1 ratio by adding 100 µL of each strain to 20 mL of LB broth (approximately 1 × 10⁵ CFU/mL each). Twenty microliters of the resulting suspension was used for serial dilutions on LB agar plates (total CFU/mL) and LB agar plates containing 16/4 µg/mL CAZ/AVI (CFU/mL of competitor strain) to receive inoculum sizes. Next, the inoculated suspension was incubated at 130 rpm and 37°C for 24 h. Finally, the CFU/mL of the strains was again determined by performing serial dilutions. The competitive indices (CIs) were calculated as the output/input ratio of the competitor compared to the reference strain.

Serum resistance and survival in bile salts. Determination of survival in 50% human serum and 50 mg/mL bile salts (an equal mixture of cholic acid and deoxycholic acid) was performed as described previously (138), with minor modifications. Briefly, overnight cultures were diluted 1:100 in 5 mL of fresh LB and incubated at 37°C and 130 rpm until the OD₆₀₀ reached 0.5 McFarland standard turbidity. Then, bacteria were pelleted (7,500 × g for 5 min at rt) and resuspended in 1 mL of PBS. One hundred microliters of sample was seeded in a 96-well microtiter plate containing 100 µL of human serum (United States origin, Sigma-Aldrich, St. Louis, MO, USA) or bile salts (100 mg/mL, dissolved in PBS; Sigma-Aldrich, St. Louis, MO, USA) per well (resulting in a final concentration of 50% human serum or 50 mg/mL bile salts and approximately 1 × 10⁸ CFU/mL). Next, 20 µL of each sample was collected, and the inoculum size was quantified by plating serial dilutions on LB agar plates incubated at 37°C overnight. The inoculated microtiter plates were incubated at 37°C without agitation for 4 h. After that, the number of survived CFU/mL was determined by plating serial dilutions and incubating at 37°C overnight. The positive control included in each experiment was the serum-resistant PBIO1289. The serum-sensitive W3110 served as the negative control. Serum resistance was expressed as log₂ fold change of CFU/mL after treatment related to inoculum size. Percent survival in bile salts was obtained by determining differences in the CFU/mL after 4 h of incubation related to the inoculum count.

Siderophore secretion. The quantitative analysis of siderophore secretion was determined using a previously described method (24), with minor modifications. First, the bacterial cultures were set to 0.5 McFarland standard turbidity in 0.9% (wt/vol) NaCl solution. Then, 50 µL of bacterial suspension was added to 15-mL polypropylene tubes (Sarstedt, Nümbrecht, Germany) containing 5 mL of chelated M9 minimal salt medium (200 µM 2,2'-dipyridyl [Carl Roth, Karlsruhe, Germany] added M9 minimal salt medium [MP Biomedicals, Irvine, CA, USA]) supplemented with 2 mM MgSO₄ (Carl Roth, Karlsruhe, Germany) and 0.3 % (wt/vol) of Casamino Acids (c-M9-CA [139]; BD, Franklin Lakes, NJ, USA). The strains were grown for 24 h at 37°C and 130 rpm. Next, 1 mL of bacterial cultures was collected in 1.5-mL tubes and centrifuged (4,900 × g for 20 min at rt), and 100 µL of siderophore-containing supernatant was transferred in triplicates to 96-well microtiter plates containing 100 µL of CAS shuttle solution (composed according to ref. 140). Additionally, fresh medium (blank) and 15 mM EDTA (positive control; Carl Roth, Karlsruhe, Germany) were included. The nonsiderophore producer ATCC 700603 served as a negative control. The mixtures were incubated in the dark for 30 min at rt, and the absorbance at a λ = 630 nm was measured using a microplate reader (CLARIOstar Plus, BMG LABTECH, Ortenberg, Germany). Secretion of siderophores was expressed as siderophore production unit in percent calculated as published previously (141).

Hypermucoviscosity. The hypermucoviscosity sedimentation assay was performed as described previously (60), with the following modifications. Again, the bacterial cultures were set to 0.5 McFarland standard turbidity in 0.9% (wt/vol) NaCl solution, and 50 µL of these bacterial suspensions was added to 5 mL of LB. Following an incubation period of 24 h at 37°C and 130 rpm, 1.5 mL of the cultures was collected in 2.0-mL tubes (Carl Roth, Karlsruhe, Germany) and centrifuged (1,000 × g for 5 min at rt). Two hundred microliters of the upper supernatant and 200 µL of the incubated culture were separately transferred each into triplicates to 96-well microtiter plates, and the OD₆₀₀ was measured. The mucoid phenotype was expressed as the ratio of supernatant to total OD₆₀₀.

Infection of *Galleria mellonella* larvae. The infections of larvae of the greater wax moth *G. mellonella* were performed as described previously (67). Briefly, 2 mL of overnight culture was collected and pelleted ($16,000 \times g$ for 5 min at rt). The pellets were washed once with PBS and diluted in PBS to an OD₆₀₀ of 1.0 turbidity (approximately 2×10^9 CFU/mL). The bacterial suspensions were further diluted to 2×10^6 CFU/mL and 2×10^7 CFU/mL, respectively. The larvae (proinsects, Minden, Germany) were randomly divided into groups with 10 individuals in each group, and 10 μ L of the bacterial suspensions was injected in the right proleg. Additionally, one group of larvae was injected with 10 μ L of PBS to ensure that death was not due to trauma from the injection. Each group was placed in 90-mm glass petri dishes kept at 37°C in the dark, and death was recorded every 24 h. Individuals were considered dead when they did not respond to physical stimuli and showed pigmentation. The results obtained with three independent assays were pooled for each strain to generate Kaplan-Meier plots of mortality rates (142).

Statistical analysis. Statistical analyses were performed using GraphPad Prism v.9.3.0 for Windows (GraphPad Software, San Diego, CA, USA). All phenotypic experiments were performed with three or more independent biological replicates. Unless otherwise specified, data were expressed as mean and standard deviation. Assessment of statistical significance was performed via analysis of variation (ANOVA) with Dunnett's multiple comparison *post hoc* test. To analyze differences in cellular uptake of CAZ, AVI, and ATM, we used a one-sample *t* test. *P* values lower than 0.05 were used to show significant statistical differences among results.

Ethics approval. Ethical approval was given by the ethics committee of the University of Greifswald, Germany (BB 133/20). Informed patient consent was waived as samples were taken under a hospital surveillance framework for routine sampling. The research conformed to the principles of the Helsinki Declaration.

Data availability. The data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number [PRJEB48690](https://www.ebi.ac.uk/ena/record/PRJEB48690). Additional data of parental strains (PBIO1953 and PBIO2003) can be found under accession number [PRJEB37933](https://www.ebi.ac.uk/ena/record/PRJEB37933).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 4 MB.

ACKNOWLEDGMENTS

We thank Martina Abs for her excellent technical assistance and Thomas A. Russo for providing the hvKP1 strain. We acknowledge financial support by Land Schleswig-Holstein within the funding programme Open Access Publikationsfonds.

We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

E.E. and K.S. conceived and designed the study. E.E., J.A.B., C.L.C.-M., and D.B. performed the laboratory and phenotypic experiments. M.S., L.S., and S.E.H. performed the bioinformatics analyses. E.E., M.S., L.S., N.-O.H., J.A.B., U.T.B., S.E.H., J.U.M., F.A., K.B., C.L.C.-M., S.G., E.A.I., D.B., and K.S. analyzed the data. E.E. and K.S. wrote the manuscript with input from all co-authors, and E.E. prepared the tables and figures. All authors read and approved the final version of the manuscript.

REFERENCES

- Heiden SE, Hübner N-O, Bohnert JA, Heidecke C-D, Kramer A, Balau V, Gierer W, Schaefer S, Eckmanns T, Gattermann S, Eger E, Guenther S, Becker K, Schaufler K. 2020. A *Klebsiella pneumoniae* ST307 outbreak clone from Germany demonstrates features of extensive drug resistance, hypermucoviscosity, and enhanced iron acquisition. *Genome Med* 12: 113. <https://doi.org/10.1186/s13073-020-00814-6>.
- Ahmed MAEE, Yang Y, Yan B, Chen G, Hassan RM, Zhong L-L, Chen Y, Roberts AP, Wu Y, He R, Liang X, Qin M, Dai M, Zhang L, Li H, Yang F, Xu L, Tian G-B. 2021. Emergence of hypervirulent carbapenem-resistant *Klebsiella pneumoniae* coharboring a *bla*_{NDM-1}-carrying cirulent clasmid and a *bla*_{KPC-2}-carrying plasmid in an Egyptian hospital. *mSphere* 6:e00088-21. <https://doi.org/10.1128/mSphere.00088-21>.
- Martin MJ, Corey BW, Sannio F, Hall LR, MacDonald U, Jones BT, Mills EG, Harless C, Stam J, Maybank R, Kwak Y, Schaufler K, Becker K, Hübner N-O, Cresti S, Tordini G, Valassina M, Cusi MG, Bennett JW, Russo TA, McGann PT, Lebreton F, Docquier J-D. 2021. Anatomy of an extensively drug-resistant *Klebsiella pneumoniae* outbreak in Tuscany, Italy. *Proc Natl Acad Sci U S A* 118:e2110227118. <https://doi.org/10.1073/pnas.2110227118>.
- Chen L, Todd R, Kiehlbauch J, Walters M, Kallen A. 2017. Notes from the field: pan-resistant New Delhi metallo-beta-lactamase-producing *Klebsiella pneumoniae* - Washoe County, Nevada, 2016. *MMWR Morb Mortal Wkly Rep* 66:33. <https://doi.org/10.15585/mmwr.mm6601a7>.
- Camargo JF, Simkins J, Beduschi T, Tekin A, Aragon L, Pérez-Cardona A, Prado CE, Morris MI, Abbo LM, Cantón R. 2015. Successful treatment of carbapenemase-producing pandrug-resistant *Klebsiella pneumoniae* bacteremia. *Antimicrob Agents Chemother* 59:5903-5908. <https://doi.org/10.1128/AAC.00655-15>.
- Papadimitriou-Olivgeris M, Bartzavali C, Georgakopoulou A, Kolonitsiou F, Papamichail C, Spiliopoulou I, Christofidou M, Fligou F, Marangos M. 2021. Mortality of pandrug-resistant *Klebsiella pneumoniae* bloodstream infections in critically ill patients: a retrospective cohort of 115 episodes. *Antibiotics (Basel)* 10:76. <https://doi.org/10.3390/antibiotics10010076>.
- Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18:268-281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outtersen K,

- Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group, Aboderin AO, Al-Abri SS, Awang Jalil N, Benzonana N, Bhattacharya S, Brink AJ, Burkert FR, Cars O, Cornaglia G, Dyar OJ, Friedrich AW, Gales AC, Gandra S, Giske CG, Goff DA, Goossens H, Gottlieb T, Guzman Blanco M, Hryniewicz W, Kattula D, Jinks T, Kanj SS, Kerr L, Kieny M-P, Kim YS, Kozlov RS, Labarca J, Laxminarayan R, Leder K, et al. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 18:318–327. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3).
9. Tyers M, Wright GD. 2019. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. *Nat Rev Microbiol* 17:141–155. <https://doi.org/10.1038/s41579-018-0141-x>.
10. Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaux C, Seys C, Stachyra T, Fairley M, Guittion M, Lampilas M. 2004. *In vitro* activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. *J Antimicrob Chemother* 54:410–417. <https://doi.org/10.1093/jac/dkh358>.
11. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C β -lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. *Antimicrob Agents Chemother* 58:5704–5713. <https://doi.org/10.1128/AAC.03057-14>.
12. Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O'Donnell JP, Bradford PA, Eakin AE. 2015. Pharmacokinetics/pharmacodynamics of a β -lactam and β -lactamase inhibitor combination: a novel approach for aztreonam/avibactam. *J Antimicrob Chemother* 70:2618–2626. <https://doi.org/10.1093/jac/dkv132>.
13. Haller S, Kramer R, Becker K, Bohnert JA, Eckmanns T, Hans JB, Hecht J, Heidecke C-D, Hübner N-O, Kramer A, Klaper K, Littmann M, Marlinghaus L, Neumann B, Pfeifer Y, Pfennigwerth N, Rogge S, Schauler K, Thürmer A, Werner G, Gatermann S. 2019. Extensively drug-resistant *Klebsiella pneumoniae* ST307 outbreak, north-eastern Germany, June to October 2019. *Eurosurveillance* 24:1900734. <https://doi.org/10.2807/1560-7917.ES.2019.24.50.1900734>.
14. Shaw E, Rombauts A, Tubau F, Padullés A, Càmarà J, Lozano T, Cobo-Sacristán S, Sabe N, Grau I, Rigo-Bonnin R, Dominguez MA, Carratalà J. 2018. Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing *Klebsiella pneumoniae* infection. *J Antimicrob Chemother* 73:1104–1106. <https://doi.org/10.1093/jac/dkx496>.
15. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant *Klebsiella* and *Enterobacter* spp. clinical isolates from the UK. *J Antimicrob Chemother* 63:659–667. <https://doi.org/10.1093/jac/dkp029>.
16. Mushtaq S, Vickers A, Ellaby N, Woodford N, Livermore DM. 2021. Selection and characterization of mutational resistance to aztreonam/avibactam in β -lactamase-producing *Enterobacterales*. *J Antimicrob Chemother* 77:98–111. <https://doi.org/10.1093/jac/dkab346>.
17. Alm RA, Johnstone MR, Lahiri SD. 2015. Characterization of *Escherichia coli* NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. *J Antimicrob Chemother* 70:1420–1428. <https://doi.org/10.1093/jac/dku568>.
18. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of β -lactamase and porin mutants of *Enterobacteriaceae* selected with ceftazidime + avibactam (NXL104). *J Antimicrob Chemother* 67:1354–1358. <https://doi.org/10.1093/jac/dks079>.
19. Fröhlich C, Sørum V, Thomassen AM, Johnsen PJ, Leiros H-KS, Samuelsen Ø. 2019. OXA-48-mediated ceftazidime-avibactam resistance is associated with evolutionary trade-offs. *mSphere* 4:e00024-19. <https://doi.org/10.1128/mSphere.00024-19>.
20. Jousset AB, Oueslati S, Emeraud C, Bonnin RA, Dortet L, Iorga BI, Naas T. 2021. KPC-39-mediated resistance to ceftazidime-avibactam in a *Klebsiella pneumoniae* ST307 clinical isolate. *Antimicrob Agents Chemother* 65:e0116021. <https://doi.org/10.1128/AAC.01160-21>.
21. Cheng DL, Liu YC, Yen MY, Liu CY, Wang RS. 1991. Septic metastatic lesions of pyogenic liver abscess. Their association with *Klebsiella pneumoniae* bacteremia in diabetic patients. *Arch Intern Med* 151:1557–1559. <https://doi.org/10.1001/archinte.1991.00400080059010>.
22. Russo TA, Marr CM. 2019. Hypervirulent *Klebsiella pneumoniae*. *Clin Microbiol Rev* 32:e00001-19. <https://doi.org/10.1128/CMR.00001-19>.
23. Lam MMC, Wyres KL, Duchêne S, Wick RR, Judd LM, Gan Y-H, Hoh C-H, Archuleta S, Molton JS, Kalimuddin S, Koh TH, Passet V, Brisse S, Holt KE. 2018. Population genomics of hypervirulent *Klebsiella pneumoniae* clonal-group 23 reveals early emergence and rapid global dissemination. *Nat Commun* 9:2703. <https://doi.org/10.1038/s41467-018-05114-7>.
24. Russo TA, Olson R, Fang C-T, Stoesser N, Miller M, MacDonald U, Hutson A, Barker JH, La Hoz RM, Johnson JR. 2018. Identification of biomarkers for differentiation of hypervirulent *Klebsiella pneumoniae* from classical *K. pneumoniae*. *J Clin Microbiol* 56:e00776-18. <https://doi.org/10.1128/JCM.00776-18>.
25. Yu W-L, Ko W-C, Cheng K-C, Lee H-C, Ke D-S, Lee C-C, Fung C-P, Chuang Y-C. 2006. Association between *rmpA* and *magA* genes and clinical syndromes caused by *Klebsiella pneumoniae* in Taiwan. *Clin Infect Dis* 42: 1351–1358. <https://doi.org/10.1086/503420>.
26. Wyres KL, Wick RR, Judd LM, Froumine R, Tokolyi A, Gorrie CL, Lam MMC, Duchêne S, Jenney A, Holt KE. 2019. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of *Klebsiella pneumoniae*. *PLoS Genet* 15:e1008114. <https://doi.org/10.1371/journal.pgen.1008114>.
27. Pomakova DK, Hsiao C-B, Beanan JM, Olson R, MacDonald U, Keynan Y, Russo TA. 2012. Clinical and phenotypic differences between classic and hypervirulent *Klebsiella pneumoniae*: an emerging and under-recognized pathogenic variant. *Eur J Clin Microbiol Infect Dis* 31:981–989. <https://doi.org/10.1007/s10096-011-1396-6>.
28. Du F-L, Huang Q-S, Wei D-D, Mei Y-F, Long D, Liao W-J, Wan L-G, Liu Y, Zhang W. 2020. Prevalence of carbapenem-resistant *Klebsiella pneumoniae* co-harboring *bla*_{KPC}-carrying plasmid and pLVPK-like virulence plasmid in bloodstream infections. *Front Cell Infect Microbiol* 10:556654. <https://doi.org/10.3389/fcimb.2020.556654>.
29. Xie Y, Tian L, Li G, Qu H, Sun J, Liang W, Li X, Wang X, Deng Z, Liu J, Ou H-Y. 2018. Emergence of the third-generation cephalosporin-resistant hypervirulent *Klebsiella pneumoniae* due to the acquisition of a self-transferable *bla*_{DHA-1}-carrying plasmid by an ST23 strain. *Virulence* 9:838–844. <https://doi.org/10.1080/21505594.2018.1456229>.
30. Karlsson M, Stanton RA, Ansari U, McAllister G, Chan MY, Sula E, Grass JE, Duffy N, Anacker ML, Witwer ML, Rasheed JK, Elkins CA, Halpin AL. 2019. Identification of a carbapenemase-producing hypervirulent *Klebsiella pneumoniae* isolate in the United States. *Antimicrob Agents Chemother* 63:e00519-19. <https://doi.org/10.1128/AAC.00519-19>.
31. Mataseje LF, Boyd DA, Mulvey MR, Longtin Y. 2019. Two hypervirulent *Klebsiella pneumoniae* isolates producing a *bla*_{KPC-2} carbapenemase from a Canadian patient. *Antimicrob Agents Chemother* 63:e00517-19. <https://doi.org/10.1128/AAC.00517-19>.
32. Rodríguez-Medina N, Martínez-Romero E, de La Cruz MA, Ares MA, Valdovinos-Torres H, Silva-Sánchez J, Lozano-Aguirre L, Martínez-Barnette J, Andrade V, Garza-Ramos U. 2020. A *Klebsiella varicola* plasmid confers hypermucoviscosity-like phenotype and alters capsule production and virulence. *Front Microbiol* 11:579612. <https://doi.org/10.3389/fmicb.2020.579612>.
33. Bowers JR, Kitchel B, Driebe EM, MacCannell DR, Roe C, Lemmer D, de Man T, Rasheed JK, Engelthaler DM, Keim P, Limbago BM. 2015. Genomic analysis of the emergence and rapid global dissemination of the clonal group 258 *Klebsiella pneumoniae* pandemic. *PLoS One* 10:e0133727. <https://doi.org/10.1371/journal.pone.0133727>.
34. Eger E, Heiden SE, Becker K, Rau A, Geisenhainer K, Idelevich EA, Schauler K. 2021. Hypervirulent *Klebsiella pneumoniae* sequence type 420 with a chromosomally inserted virulence plasmid. *Int J Mol Sci* 22:9196. <https://doi.org/10.3390/ijms2219196>.
35. Lam MMC, Wick RR, Wyres KL, Gorrie CL, Judd LM, Jenney AWJ, Brisse S, Holt KE. 2018. Genetic diversity, mobilisation and spread of the yersiniabactin-encoding mobile element ICE_{Kp} in *Klebsiella pneumoniae* populations. *Microb Genom* 4:e000196. <https://doi.org/10.1099/mgen.0.000196>.
36. David S, Cohen V, Reuter S, Sheppard AE, Giani T, Parkhill J, European Survey of Carbapenemase-Producing *Enterobacteriaceae* (EuSCAPE) Working Group, ESCMID Study Group for Epidemiological Markers (ESGEM), Rossolini GM, Feil EJ, Grundmann H, Aanensen DM. 2020. Integrated chromosomal and plasmid sequence analyses reveal diverse modes of carbapenemase gene spread among *Klebsiella pneumoniae*. *Proc Natl Acad Sci U S A* 117:25043–25054. <https://doi.org/10.1073/pnas.2003407117>.
37. Jin L, Wang R, Gao H, Wang Q, Wang H. 2021. Identification of a novel hybrid plasmid encoding KPC-2 and virulence factors in *Klebsiella pneumoniae* sequence type 11. *Antimicrob Agents Chemother* 65:e02435-20. <https://doi.org/10.1128/AAC.02435-20>.
38. Xie M, Chen K, Ye L, Yang X, Xu Q, Yang C, Dong N, Chan EW-C, Sun Q, Shu L, Gu D, Lin X, Zhang R, Chen S. 2020. Conjugation of virulence plasmid in clinical *Klebsiella pneumoniae* strains through formation of a

- fusion plasmid. *Adv Biosyst* 4:e1900239. <https://doi.org/10.1002/adbi.201900239>.
39. Handel A, Regoes RR, Antia R. 2006. The role of compensatory mutations in the emergence of drug resistance. *PLoS Comput Biol* 2:e137. <https://doi.org/10.1371/journal.pcbi.0020137>.
 40. Costanzo M, VanderSluis B, Koch EN, Baryshnikova A, Pons C, Tan G, Wang W, Usaj M, Hanchard J, Lee SD, Pelechano V, Styles EB, Billmann M, van Leeuwen J, van Dyk N, Lin Z-Y, Kuzmin E, Nelson J, Piotrowski JS, Srikumar T, Bahr S, Chen Y, Deshpande R, Kurat CF, Li SC, Li Z, Usaj MM, Okada H, Pascoe N, San Luis B-J, Sharifpoor S, Shuteriqi E, Simpkins SW, Snider J, Suresh HG, Tan Y, Zhu H, Malod-Dognin N, Janjic V, Przulj N, Troyanskaya OG, Stagljar I, Xia T, Ohya Y, Gingras A-C, Raught B, Boutros M, Steinmetz LM, Moore CL, Rosebrock AP, et al. 2016. A global genetic interaction network maps a wiring diagram of cellular function. *Science* 353:aaf1420. <https://doi.org/10.1126/science.aaf1420>.
 41. Blin C, Passet V, Touchon M, Rocha EPC, Brisse S. 2017. Metabolic diversity of the emerging pathogenic lineages of *Klebsiella pneumoniae*. *Environ Microbiol* 19:1881–1898. <https://doi.org/10.1111/1462-2920.13689>.
 42. The European Committee on Antimicrobial Susceptibility Testing. 2021. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. <http://www.eucast.org>. Accessed October 12, 2021.
 43. Acosta-Gutiérrez S, Ferrara L, Pathania M, Masi M, Wang J, Bodrenko I, Zahn M, Winterhalter M, Stavenger RA, Pagès J-M, Naismith JH, van den Berg B, Page MGP, Ceccarelli M. 2018. Getting drugs into Gram-negative bacteria: rational rules for permeation through general porins. *ACS Infect Dis* 4:1487–1498. <https://doi.org/10.1021/acsinfecdis.8b00108>.
 44. Abellón-Ruiz J, Kaptan SS, Baslé A, Claudi B, Bumann D, Kleinekathöfer U, van den Berg B. 2017. Structural basis for maintenance of bacterial outer membrane lipid asymmetry. *Nat Microbiol* 2:1616–1623. <https://doi.org/10.1038/s41564-017-0046-x>.
 45. Weber M, Burgos R, Yus E, Yang J-S, Lluich-Senar M, Serrano L. 2020. Impact of C-terminal amino acid composition on protein expression in bacteria. *Mol Syst Biol* 16:e9208. <https://doi.org/10.1525/msb.20199208>.
 46. Rietsch A, Belin D, Martin N, Beckwith J. 1996. An *in vivo* pathway for disulfide bond isomerization in *Escherichia coli*. *Proc Natl Acad Sci U S A* 93:13048–13053. <https://doi.org/10.1073/pnas.93.23.13048>.
 47. Bardwell JC, McGovern K, Beckwith J. 1991. Identification of a protein required for disulfide bond formation *in vivo*. *Cell* 67:581–589. [https://doi.org/10.1016/0092-8674\(91\)90532-4](https://doi.org/10.1016/0092-8674(91)90532-4).
 48. Wand ME, Bock LJ, Bonney LC, Sutton JM. 2017. Mechanisms of increased resistance to chlorhexidine and cross-resistance to colistin following exposure of *Klebsiella pneumoniae* clinical isolates to chlorhexidine. *Antimicrob Agents Chemother* 61:e01162-16. <https://doi.org/10.1128/AAC.01162-16>.
 49. Imamovic L, Ellabaan MMH, Dantas Machado AM, Citterio L, Wulff T, Molin S, Krogh Johansen H, Sommer MOA. 2018. Drug-driven phenotypic convergence supports rational treatment strategies of chronic infections. *Cell* 172:121–134. <https://doi.org/10.1016/j.cell.2017.12.012>.
 50. Barbosa C, Römhild R, Rosenstiel P, Schulenburg H. 2019. Evolutionary stability of collateral sensitivity to antibiotics in the model pathogen *Pseudomonas aeruginosa*. *eLife* 8:e51481. <https://doi.org/10.7554/eLife.51481>.
 51. Srinivasan VB, Venkataramaiah M, Mondal A, Vaidyanathan V, Govil T, Rajamohan G. 2012. Functional characterization of a novel outer membrane porin KpnO, regulated by PhoBR two-component system in *Klebsiella pneumoniae* NTUH-K2044. *PLoS One* 7:e41505. <https://doi.org/10.1371/journal.pone.0041505>.
 52. García-Sureda L, Doménech-Sánchez A, Barbier M, Juan C, Gascó J, Alberti S. 2011. OmpK26, a novel porin associated with carbapenem resistance in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 55:4742–4747. <https://doi.org/10.1128/AAC.00309-11>.
 53. Tsai Y-K, Fung C-P, Lin J-C, Chen J-H, Chang F-Y, Chen T-L, Siu LK. 2011. *Klebsiella pneumoniae* outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence. *Antimicrob Agents Chemother* 55:1485–1493. <https://doi.org/10.1128/AAC.01275-10>.
 54. Wong JLC, Romano M, Kerry LE, Kwong H-S, Low W-W, Brett SJ, Clements A, Beis K, Frankel G. 2019. OmpK36-mediated carbapenem resistance attenuates ST258 *Klebsiella pneumoniae* *in vivo*. *Nat Commun* 10:3957. <https://doi.org/10.1038/s41467-019-11756-y>.
 55. Fajardo-Lubián A, Ben Zakour NL, Agyekum A, Qi Q, Iredell JR. 2019. Host adaptation and convergent evolution increases antibiotic resistance without loss of virulence in a major human pathogen. *PLoS Pathog* 15:e1007218. <https://doi.org/10.1371/journal.ppat.1007218>.
 56. Neillands JB. 1995. Siderophores: structure and function of microbial iron transport compounds. *J Biol Chem* 270:26723–26726. <https://doi.org/10.1074/jbc.270.45.26723>.
 57. Russo TA, Olson R, MacDonald U, Metzger D, Maltese LM, Drake EJ, Gulick AM. 2014. Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) *Klebsiella pneumoniae*. *Infect Immun* 82:2356–2367. <https://doi.org/10.1128/IAI.01667-13>.
 58. Lawlor MS, Hsu J, Rick PD, Miller VL. 2005. Identification of *Klebsiella pneumoniae* virulence determinants using an intranasal infection model. *Mol Microbiol* 58:1054–1073. <https://doi.org/10.1111/j.1365-2958.2005.04918.x>.
 59. Yoshida K, Matsumoto T, Tateda K, Uchida K, Tsujimoto S, Yamaguchi K. 2000. Role of bacterial capsule in local and systemic inflammatory responses of mice during pulmonary infection with *Klebsiella pneumoniae*. *J Med Microbiol* 49:1003–1010. <https://doi.org/10.1099/0022-1317-49-11-1003>.
 60. Mike LA, Stark AJ, Forsyth VS, Vornhagen J, Smith SN, Bachman MA, Mobley HLT. 2021. A systematic analysis of hypermucoviscosity and capsule reveals distinct and overlapping genes that impact *Klebsiella pneumoniae* fitness. *PLoS Pathog* 17:e1009376. <https://doi.org/10.1371/journal.ppat.1009376>.
 61. Chung DR, Lee SS, Lee HR, Kim HB, Choi HJ, Eom JS, Kim JS, Choi YH, Lee JS, Chung MH, Kim YS, Lee H, Lee MS, Park CK, Korean Study Group for Liver Abscess. 2007. Emerging invasive liver abscess caused by K1 serotype *Klebsiella pneumoniae* in Korea. *J Infect* 54:578–583. <https://doi.org/10.1016/j.jinf.2006.11.008>.
 62. Wu K-M, Li L-H, Yan J-J, Tsao N, Liao T-L, Tsai H-C, Fung C-P, Chen H-J, Liu Y-M, Wang J-T, Fang C-T, Chang S-C, Shu H-Y, Liu T-T, Chen Y-T, Shiao Y-R, Lauderdale T-L, Su I-J, Kirby R, Tsai S-F. 2009. Genome sequencing and comparative analysis of *Klebsiella pneumoniae* NTUH-K2044, a strain causing liver abscess and meningitis. *J Bacteriol* 191:4492–4501. <https://doi.org/10.1128/JB.00315-09>.
 63. Siu LK, Yeh K-M, Lin J-C, Fung C-P, Chang F-Y. 2012. *Klebsiella pneumoniae* liver abscess: a new invasive syndrome. *Lancet Infect Dis* 12:881–887. [https://doi.org/10.1016/S1473-3099\(12\)70205-0](https://doi.org/10.1016/S1473-3099(12)70205-0).
 64. Lin Y-T, Wang F-D, Wu P-F, Fung C-P. 2013. *Klebsiella pneumoniae* liver abscess in diabetic patients: association of glycemic control with the clinical characteristics. *BMC Infect Dis* 13:56. <https://doi.org/10.1186/1471-2334-13-56>.
 65. Stotka JL, Rupp ME. 1991. *Klebsiella pneumoniae* urinary tract infection complicated by endophthalmitis, perinephric abscess, and ecthyma gangrenosum. *South Med J* 84:790–793. <https://doi.org/10.1097/00007611-199106000-00032>.
 66. Ko W-C, Paterson DL, Sagnimeni AJ, Hansen DS, von Gottberg A, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, McCormack JG, Yu VL. 2002. Community-acquired *Klebsiella pneumoniae* bacteremia: global differences in clinical patterns. *Emerg Infect Dis* 8:160–166. <https://doi.org/10.3201/eid0802.010025>.
 67. Insua JL, Llobet E, Moranta D, Pérez-Gutiérrez C, Tomás A, Garmendia J, Bengoechea JA. 2013. Modeling *Klebsiella pneumoniae* pathogenesis by infection of the wax moth *Galleria mellonella*. *Infect Immun* 81:3552–3565. <https://doi.org/10.1128/IAI.00391-13>.
 68. Maisnier-Patin S, Andersson DI. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. *Res Microbiol* 155:360–369. <https://doi.org/10.1016/j.resmic.2004.01.019>.
 69. Knöppel A, Knopp M, Albrecht LM, Lundin E, Lustig U, Näsvall J, Andersson DI. 2018. Genetic adaptation to growth under laboratory conditions in *Escherichia coli* and *Salmonella enterica*. *Front Microbiol* 9:756. <https://doi.org/10.3389/fmicb.2018.00756>.
 70. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. *Science* 287:1479–1482. <https://doi.org/10.1126/science.287.5457.1479>.
 71. Sezonov G, Joseleau-Petit D, D'Ari R. 2007. *Escherichia coli* physiology in Luria-Bertani broth. *J Bacteriol* 189:8746–8749. <https://doi.org/10.1128/JB.01368-07>.
 72. Mecas J, Rouviere PE, Erickson JW, Donohue TJ, Gross CA. 1993. The activity of sigma E, an *Escherichia coli* heat-inducible sigma-factor, is modulated by expression of outer membrane proteins. *Genes Dev* 7:2618–2628. <https://doi.org/10.1101/gad.7.12b.2618>.
 73. Rowley G, Spector M, Kormanec J, Roberts M. 2006. Pushing the envelope: extracytoplasmic stress responses in bacterial pathogens. *Nat Rev Microbiol* 4:383–394. <https://doi.org/10.1038/nrmicro1394>.

74. Kabir MS, Yamashita D, Koyama S, Oshima T, Kurokawa K, Maeda M, Tsunedomi R, Murata M, Wada C, Mori H, Yamada M. 2005. Cell lysis directed by sigmaE in early stationary phase and effect of induction of the *rpoE* gene on global gene expression in *Escherichia coli*. *Microbiology (Reading)* 151:2721–2735. <https://doi.org/10.1099/mic.0.28004-0>.
75. Dartigalongue C, Missiakos D, Raina S. 2001. Characterization of the *Escherichia coli* sigma E regulon. *J Biol Chem* 276:20866–20875. <https://doi.org/10.1074/jbc.M100464200>.
76. Fang C, Li L, Shen L, Shi J, Wang S, Feng Y, Zhang Y. 2019. Structures and mechanism of transcription initiation by bacterial ECF factors. *Nucleic Acids Res* 47:7094–7104. <https://doi.org/10.1093/nar/gkz470>.
77. Tomatis PE, Schütz M, Umudumov E, Plückthun A. 2019. Mutations in sigma 70 transcription factor improves expression of functional eukaryotic membrane proteins in *Escherichia coli*. *Sci Rep* 9:2483. <https://doi.org/10.1038/s41598-019-39492-9>.
78. Wheatley R, Diaz Caballero J, Kapel N, de Winter FHR, Jangir P, Quinn A, Del Barrio-Tofiño E, López-Causapé C, Hedge J, Torrens G, van der Schalk T, Xavier BB, Fernández-Cuenca F, Arenzana A, Recanatini C, Timbermont L, Sifakis F, Ruzin A, Ali O, Lammens C, Goossens H, Kluytmans J, Kumar-Singh S, Oliver A, Malhotra-Kumar S, MacLean C. 2021. Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute *Pseudomonas aeruginosa* infection. *Nat Commun* 12:2460. <https://doi.org/10.1038/s41467-021-22814-9>.
79. Avican K, Aldahdoo H, Togninalli M, Mahmud AKMF, Tang J, Borgwardt KM, Rhen M, Fällman M. 2021. RNA atlas of human bacterial pathogens uncovers stress dynamics linked to infection. *Nat Commun* 12:3282. <https://doi.org/10.1038/s41467-021-23588-w>.
80. Zhu Z, Surujon D, Ortiz-Marquez JC, Huo W, Isberg RR, Bento J, van Opijnen T. 2020. Entropy of a bacterial stress response is a generalizable predictor for fitness and antibiotic sensitivity. *Nat Commun* 11:4365. <https://doi.org/10.1038/s41467-020-18134-z>.
81. Bury-Moné S, Nomane Y, Reymond N, Barbet R, Jacquet E, Imbeaud S, Jacq A, Boulloc P. 2009. Global analysis of extracytoplasmic stress signaling in *Escherichia coli*. *PLoS Genet* 5:e1000651. <https://doi.org/10.1371/journal.pgen.1000651>.
82. Vogt J, Schulz GE. 1999. The structure of the outer membrane protein OmpX from *Escherichia coli* reveals possible mechanisms of virulence. *Structure* 7:1301–1309. [https://doi.org/10.1016/S0969-2126\(00\)80063-5](https://doi.org/10.1016/S0969-2126(00)80063-5).
83. Li B, Huang Q, Cui A, Liu X, Hou B, Zhang L, Liu M, Meng X, Li S. 2018. Overexpression of outer membrane protein X (OmpX) compensates for the effect of TolC inactivation on biofilm formation and curli production in extraintestinal pathogenic *Escherichia coli* (ExPEC). *Front Cell Infect Microbiol* 8:208. <https://doi.org/10.3389/fcimb.2018.00208>.
84. Meng X, Liu X, Zhang L, Hou B, Li B, Tan C, Li Z, Zhou R, Li S. 2016. Virulence characteristics of extraintestinal pathogenic *Escherichia coli* deletion of gene encoding the outer membrane protein X. *J Vet Med Sci* 78:1261–1267. <https://doi.org/10.1292/jvms.16-0071>.
85. Padan E. 2008. The enlightening encounter between structure and function in the NhaA Na⁺-H⁺ antiporter. *Trends Biochem Sci* 33:435–443. <https://doi.org/10.1016/j.tibs.2008.06.007>.
86. Zhang H, Chen X, Nolan LK, Zhang W, Li G. 2019. Identification of host adaptation genes in extraintestinal pathogenic *Escherichia coli* during infection in different hosts. *Infect Immun* 87:e00666-19. <https://doi.org/10.1128/IAI.00666-19>.
87. Minato Y, Ghosh A, Faulkner WJ, Lind EJ, Schesser Bartra S, Plano GV, Jarrett CO, Hinnebusch BJ, Winogrodzki J, Dibrov P, Häse CC. 2013. Na⁺/H⁺ antiporter is essential for *Yersinia pestis* virulence. *Infect Immun* 81:3163–3172. <https://doi.org/10.1128/IAI.00071-13>.
88. Ross W, Sanchez-Vazquez P, Chen AY, Lee J-H, Burgos HL, Gourse RL. 2016. ppGpp binding to a site at the RNAP-DksA interface accounts for its dramatic effects on transcription initiation during the stringent response. *Mol Cell* 62:811–823. <https://doi.org/10.1016/j.molcel.2016.04.029>.
89. Paul BJ, Barker MM, Ross W, Schneider DA, Webb C, Foster JW, Gourse RL. 2004. DksA: a critical component of the transcription initiation machinery that potentiates the regulation of rRNA promoters by ppGpp and the initiating NTP. *Cell* 118:311–322. <https://doi.org/10.1016/j.cell.2004.07.009>.
90. Velkov T, Deris ZZ, Huang JX, Azad MAK, Butler M, Sivanesan S, Kaminskas LM, Dong Y-D, Boyd B, Baker MA, Cooper MA, Nation RL, Li J. 2014. Surface changes and polymyxin interactions with a resistant strain of *Klebsiella pneumoniae*. *Innate Immun* 20:350–363. <https://doi.org/10.1177/1753425913493337>.
91. Hegreness M, Shores N, Damian D, Hartl D, Kishony R. 2008. Accelerated evolution of resistance in multidrug environments. *Proc Natl Acad Sci U S A* 105:13977–13981. <https://doi.org/10.1073/pnas.0805965105>.
92. Kohanski MA, DePristo MA, Collins JJ. 2010. Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis. *Mol Cell* 37:311–320. <https://doi.org/10.1016/j.molcel.2010.01.003>.
93. Shirley M. 2018. Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections. *Drugs* 78:675–692. <https://doi.org/10.1007/s40265-018-0902-x>.
94. Mendes RE, Doyle TB, Streit JM, Arhin FF, Sader HS, Castanheira M. 2021. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. *J Antimicrob Chemother* 76:2833–2838. <https://doi.org/10.1093/jac/dkab279>.
95. Nordmann P, Yao Y, Falgenhauer L, Sadek M, Imirziloglu C, Chakraborty T. 2021. Recent emergence of aztreonam-avibactam resistance in NDM and OXA-48 carbapenemase-producing *Escherichia coli* in Germany. *Antimicrob Agents Chemother* 65:e0109021. <https://doi.org/10.1128/AAC.01090-21>.
96. Kong H-K, Pan Q, Lo W-U, Liu X, Law COK, Chan T-F, Ho P-L, Lau TC-K. 2018. Fine-tuning carbapenem resistance by reducing porin permeability of bacteria activated in the selection process of conjugation. *Sci Rep* 8:15248. <https://doi.org/10.1038/s41598-018-33568-8>.
97. Wise MG, Horvath E, Young K, Sahn DF, Kazmierczak KM. 2018. Global survey of *Klebsiella pneumoniae* major porins from ertapenem non-susceptible isolates lacking carbapenemases. *J Med Microbiol* 67:289–295. <https://doi.org/10.1099/jmm.0.000691>.
98. Castanheira M, Mendes RE, Sader HS. 2017. Low frequency of ceftazidime-avibactam resistance among *Enterobacteriaceae* isolates carrying bla_{KPC} collected in U.S. hospitals from 2012 to 2015. *Antimicrob Agents Chemother* 61:e02369-16. <https://doi.org/10.1128/AAC.02369-16>.
99. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. 2021. A genomic surveillance framework and genotyping tool for *Klebsiella pneumoniae* and its related species complex. *Nat Commun* 12:4188. <https://doi.org/10.1038/s41467-021-24448-3>.
100. Pagès J-M, Peslier S, Keating TA, Lavigne J-P, Nichols WW. 2015. Role of the outer membrane and porins in susceptibility of β -lactamase-producing *Enterobacteriaceae* to ceftazidime-avibactam. *Antimicrob Agents Chemother* 60:1349–1359. <https://doi.org/10.1128/AAC.01585-15>.
101. Beceiro A, Tomás M, Bou G. 2013. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? *Clin Microbiol Rev* 26:185–230. <https://doi.org/10.1128/CMR.00059-12>.
102. Carroll AC, Wong A. 2018. Plasmid persistence: costs, benefits, and the plasmid paradox. *Can J Microbiol* 64:293–304. <https://doi.org/10.1139/cjm-2017-0609>.
103. Schaufler K, Semmler T, Pickard DJ, de Toro M, de la Cruz F, Wieler LH, Ewers C, Guenther S. 2016. Carriage of extended-spectrum beta-lactamase-plasmids does not reduce fitness but enhances virulence in some strains of pandemic *E. coli* lineages. *Front Microbiol* 7:336. <https://doi.org/10.3389/fmicb.2016.00336>.
104. Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, Peirano G, Bonnedahl J, Dolejska M, Literak I, Fuchs S, Ahmed N, Grobbel M, Torres C, McNally A, Pickard D, Ewers C, Croucher NJ, Corander J, Guenther S. 2019. Genomic and functional analysis of emerging virulent and multidrug-resistant *Escherichia coli* lineage sequence type 648. *Antimicrob Agents Chemother* 63:e00243-19. <https://doi.org/10.1128/AAC.00243-19>.
105. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, Endimiani A, Mammica C, Ocampo AM, Jimenez JN, Doumith M, Woodford N, Hopkins K, Carattoli A. 2017. Diversity, virulence, and antimicrobial resistance of the KPC-producing *Klebsiella pneumoniae* ST307 clone. *Microb Genom* 3:e000110. <https://doi.org/10.1099/mgen.0.000110>.
106. Turton J, Davies F, Turton J, Perry C, Payne Z, Pike R. 2019. Hybrid resistance and virulence plasmids in “high-risk” clones of *Klebsiella pneumoniae*, including those carrying bla_{KDM-5}. *Microorganisms* 7:326. <https://doi.org/10.3390/microorganisms7090326>.
107. Eger E, Heiden SE, Korolew K, Bayingana C, Ndoli JM, Sendegaya A, Gahutu JB, Kurz MSE, Mockenhaupt FP, Müller J, Simm S, Schaufler K. 2021. Circulation of extended-spectrum beta-lactamase-producing *Escherichia coli* of pandemic sequence types 131, 648, and 410 among hospitalized patients, caregivers, and the community in Rwanda. *Front Microbiol* 12:662575. <https://doi.org/10.3389/fmicb.2021.662575>.
108. Schierack P, Heiden SE, Khan MM, Nikolaus L, Kolenda R, Stubbe M, Lkhagvasuren D, Rödiger S, Guenther S, Schaufler K. 2020. Genomic and phenotypic analysis of an ESBL-producing *E. coli* ST1159 clonal lineage from wild birds in Mongolia. *Front Microbiol* 11:1699. <https://doi.org/10.3389/fmicb.2020.01699>.
109. Delgado-Gardea MCE, Tamez-Guerra P, Gomez-Flores R, Zavala-Díaz de la Serna FJ, Eroza-de la Vega G, Nevárez-Moorillón GV, Pérez-Recoder

- MC, Sánchez-Ramírez B, Del Carmen González-Horta M, Infante-Ramírez R. 2016. Multidrug-resistant bacteria isolated from surface water in Basaseachic Falls National Park, Mexico. *Int J Environ Res Public Health* 13: 597. <https://doi.org/10.3390/ijerph13060597>.
110. Imchen M, Vennapu RK, Ghosh P, Kumavath R. 2019. Insights into antagonistic interactions of multidrug resistant bacteria in mangrove sediments from the South Indian state of Kerala. *Microorganisms* 7:678. <https://doi.org/10.3390/microorganisms7120678>.
111. Moura de Sousa J, Balbontin R, Durão P, Gordo I. 2017. Multidrug-resistant bacteria compensate for the epistasis between resistances. *PLoS Biol* 15:e2001741. <https://doi.org/10.1371/journal.pbio.2001741>.
112. Bartell JA, Sommer LM, Haagensen JAJ, Loch A, Espinosa R, Molin S, Johansen HK. 2019. Evolutionary highways to persistent bacterial infection. *Nat Commun* 10:629. <https://doi.org/10.1038/s41467-019-08504-7>.
113. Mahrt N, Tietze A, Künzel S, Franzenburg S, Barbosa C, Jansen G, Schulenburg H. 2021. Bottleneck size and selection level reproducibly impact evolution of antibiotic resistance. *Nat Ecol Evol* 5:1233–1242. <https://doi.org/10.1038/s41559-021-01511-2>.
114. Hussein KE, Bahey-El-Din M, Sheweita SA. 2018. Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against *Klebsiella pneumoniae* in the murine infection model. *Microb Pathog* 119:12–18. <https://doi.org/10.1016/j.micpath.2018.04.004>.
115. Babu L, Uppalapati SR, Sripathy MH, Reddy PN. 2017. Evaluation of recombinant multi-epitope outer membrane protein-based *Klebsiella pneumoniae* subunit vaccine in mouse model. *Front Microbiol* 8:1805. <https://doi.org/10.3389/fmicb.2017.01805>.
116. Kurupati P, Ramachandran NP, Poh CL. 2011. Protective efficacy of DNA vaccines encoding outer membrane protein A and OmpK36 of *Klebsiella pneumoniae* in mice. *Clin Vaccine Immunol* 18:82–88. <https://doi.org/10.1128/CI.00275-10>.
117. Kawecki TJ, Lenski RE, Ebert D, Hollis B, Olivieri I, Whitlock MC. 2012. Experimental evolution. *Trends Ecol Evol* 27:547–560. <https://doi.org/10.1016/j.tree.2012.06.001>.
118. Wahl LM, Gerrish PJ. 2001. The probability that beneficial mutations are lost in populations with periodic bottlenecks. *Evolution* 55:2606–2610. <https://doi.org/10.1111/j.0014-3820.2001.tb00772.x>.
119. Deatherage DE, Barrick JE. 2014. Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq. *Methods Mol Biol* 1151:165–188. https://doi.org/10.1007/978-1-4939-0554-6_12.
120. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Pribelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol* 19:455–477. <https://doi.org/10.1089/cmb.2012.0021>.
121. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 25:1754–1760. <https://doi.org/10.1093/bioinformatics/btp324>.
122. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. *Bioinformatics* 25:2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
123. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9:e112963. <https://doi.org/10.1371/journal.pone.0112963>.
124. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9:357–359. <https://doi.org/10.1038/nmeth.1923>.
125. Liao Y, Smyth GK, Shi W. 2014. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* 30:923–930. <https://doi.org/10.1093/bioinformatics/btt656>.
126. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550. <https://doi.org/10.1186/s13059-014-0550-8>.
127. Church NJ, Schofield P, Gierliński M, Cole C, Sherstnev A, Singh V, Wrobel N, Gharbi K, Simpson GG, Owen-Hughes T, Blaxter M, Barton GJ. 2016. How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use? *RNA* 22: 839–851. <https://doi.org/10.1261/ma.053959.115>.
128. Galperin MY, Wolf YI, Makarova KS, Vera Alvarez R, Landsman D, Koonin EV. 2021. COG database update: focus on microbial diversity, model organisms, and widespread pathogens. *Nucleic Acids Res* 49:D274–D281. <https://doi.org/10.1093/nar/gkaa1018>.
129. Tatusov RL, Koonin EV, Lipman DJ. 1997. A genomic perspective on protein families. *Science* 278:631–637. <https://doi.org/10.1126/science.278.5338.631>.
130. Buchfink B, Reuter K, Drost H-G. 2021. Sensitive protein alignments at tree-of-life scale using DIAMOND. *Nat Methods* 18:366–368. <https://doi.org/10.1038/s41592-021-01101-x>.
131. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. 2013. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* 27:221–234. <https://doi.org/10.1007/s10822-013-9644-8>.
132. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. 2005. Scalable molecular dynamics with NAMD. *J Comput Chem* 26:1781–1802. <https://doi.org/10.1002/jcc.20289>.
133. Jo S, Kim T, Iyer VG, Im W. 2008. CHARMM-GUI: a web-based graphical user interface for CHARMM. *J Comput Chem* 29:1859–1865. <https://doi.org/10.1002/jcc.20945>.
134. Hopkins CW, Le Grand S, Walker RC, Roitberg AE. 2015. Long-time-step molecular dynamics through hydrogen mass repartitioning. *J Chem Theory Comput* 11:1864–1874. <https://doi.org/10.1021/ct5010406>.
135. Jacobson MP, Pincus DL, Rapp CS, Day TJF, Honig B, Shaw DE, Friesner RA. 2004. A hierarchical approach to all-atom protein loop prediction. *Proteins* 55:351–367. <https://doi.org/10.1002/prot.10613>.
136. Baecker D, Sesli Ö, Knabl L, Huber S, Orth-Höller D, Gust R. 2021. Investigating the antibacterial activity of salen/salophene metal complexes: induction of ferroptosis as part of the mode of action. *Eur J Med Chem* 209:112907. <https://doi.org/10.1016/j.ejmech.2020.112907>.
137. Ferreira HS, Lepri FG, Welz B, Carasek E, Huang M-D. 2010. Determination of sulfur in biological samples using high-resolution molecular absorption spectrometry in a graphite furnace with direct solid sampling. *J Anal At Spectrom* 25:1039. <https://doi.org/10.1039/b925739j>.
138. Ranjan A, Scholz J, Semmler T, Wieler LH, Ewers C, Müller S, Pickard DJ, Schierack P, Tedin K, Ahmed N, Schaeffler K, Guenther S. 2018. ESBL-plasmid carriage in *E. coli* enhances *in vitro* bacterial competition fitness and serum resistance in some strains of pandemic sequence types without overall fitness cost. *Gut Pathog* 10:24. <https://doi.org/10.1186/s13099-018-0243-z>.
139. Bulger J, MacDonald U, Olson R, Beanan J, Russo TA. 2017. Metabolite transporter PEG344 is required for full virulence of hypervirulent *Klebsiella pneumoniae* strain hvKP1 after pulmonary but not subcutaneous challenge. *Infect Immun* 85:e00093-17. <https://doi.org/10.1128/IAI.00093-17>.
140. Himpel SD, Mobley HLT. 2019. Siderophore detection using chrome azurol S and cross-feeding assays. *Methods Mol Biol* 2021:97–108. https://doi.org/10.1007/978-1-4939-9601-8_10.
141. Arora NK, Verma M. 2017. Modified microplate method for rapid and efficient estimation of siderophore produced by bacteria. *3 Biotech* 7:381. <https://doi.org/10.1007/s13205-017-1008-y>.
142. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457–481. <https://doi.org/10.1080/01621459.1958.10501452>.
143. Rasheed JK, Anderson GJ, Yigit H, Queenan AM, Doménech-Sánchez A, Swenson JM, Biddle JW, Ferraro MJ, Jacoby GA, Tenover FC. 2000. Characterization of the extended-spectrum beta-lactamase reference strain, *Klebsiella pneumoniae* K6 (ATCC 700603), which produces the novel enzyme SHV-18. *Antimicrob Agents Chemother* 44:2382–2388. <https://doi.org/10.1128/AAC.44.9.2382-2388.2000>.
144. Russo TA, Gill SR. 2013. Draft genome sequence of the hypervirulent *Klebsiella pneumoniae* strain hvKP1, isolated in Buffalo, New York. *Genome Announc* 1:e0006513. <https://doi.org/10.1128/genomeA.00065-13>.
145. Ewers C, Antão E-M, Diehl I, Philipp H-C, Wieler LH. 2009. Intestine and environment of the chicken as reservoirs for extraintestinal pathogenic *Escherichia coli* strains with zoonotic potential. *Appl Environ Microbiol* 75:184–192. <https://doi.org/10.1128/AEM.01324-08>.
146. Hayashi K, Morooka N, Yamamoto Y, Fujita K, Isono K, Choi S, Ohtsubo E, Baba T, Wanner BL, Mori H, Horiuchi T. 2006. Highly accurate genome sequences of *Escherichia coli* K-12 strains MG1655 and W3110. *Mol Syst Biol* 2:2006.0007. <https://doi.org/10.1038/msb4100049>.